Alerta

NEW METHOD FOR DELIVERING COMPOUNDS OF INTEREST

Resumen de: AU2025231263A1

The present invention provides a delivery system comprising of a first aqueous composition harbouring small particles and a second aqueous composition harbouring larger particles in which the particles of the first and second aqueous compositions may comprise the same or a different compound of interest, wherein said compound of interest preferably is a hydrophobic or amphiphilic compound. In both cases the small particles comprise a partly liquid oil phase at temperatures around about 4°C.

METHODS OF IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTIC AGENTS

Resumen de: US20260263380A1

This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.

LIPID NANOPARTICLES COMPRISING CODING RNA MOLECULES FOR USE IN GENE EDITING AND AS VACCINES AND THERAPEUTIC AGENTS

Resumen de: AU2025223541A1

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.

DELIVERY COMPOSITIONS

Resumen de: AU2025223640A1

This disclosure provides, for instance, novel lipids suitable for use in lipid nanoparticles, for therapeutic delivery of nucleic acids. Also provided are methods of making and using the lipids.

METHODS FOR FUS-BASED DELIVERY OF VIRAL PARTICLES TO THE BRAIN

Resumen de: AU2025212867A1

Provided herein are methods to treat various neurodegenerative disorders comprising delivering a viral particles to the whole brain, including both superficial and deep structures. In some aspects, the viral particles are administered at low dose levels to the CSF, in conjunction with microbubbles followed by application of focused ultrasound (FUS) to a region of interest of the brain, thereby causing entry of the viral particles to the brain.

COMPOSITIONS AND METHODS

Resumen de: US20260263372A1

An aqueous dispersion having an aqueous mobile phase and a dispersed phase; wherein the dispersed phase comprises a lipid mixture including a cationically ionisable lipid; and the aqueous mobile phase comprises an anion of an aqueous acid; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents and RNA, is described. Methods of preparing the aqueous dispersion, nucleic acid-lipid particles and methods of preparing them using the aqueous dispersion, and their use in medicine are disclosed.

ANTI-ALBUMIN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF

Resumen de: AU2025211997A1

Provided are an anti-albumin antibody or an antigen-binding fragment thereof and the use thereof, and an anti-albumin nanobody with improved affinity or an antigen-binding fragment thereof. The anti-albumin antibodies or antigen-binding fragments thereof can bind to albumins from different species with high affinity. In addition, the anti-albumin antibody can be linked to a bioactive effector molecule to form a fusion construct without affecting the activity of the bioactive effector molecule.

Novel Anti-HSV Antibody

Resumen de: US20260265348A1

Described is a (first) anti-HSV antibody or an antigen-binding fragment thereof binding to the glycoprotein B (gB) of HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said antibody or antigen-binding fragment has a low dissociation rate kdis of at most 5.0×10−4 s−1, preferably at most 1.0×10−4 s−1, at most 5.0×10−5 s−1, and most preferably at most 2.9×10−5 s−1. Moreover, described is a combination of (A) said (first) anti-HSV antibody or an antigen-binding fragment thereof; and (B) a second anti-HSV antibody or an antigen-binding fragment thereof recognizing/binding to the glycoprotein B (gB) of the HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Further, described is a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or the antigen-binding fragment thereof or the combination of said antibodies and at least one pharmaceutically acceptable excipient. Further, described is an anti-HSV antibody or the antigen-binding fragment t

NUCLEIC ACIDS ENCODING THERAPEUTIC POLYPEPTIDES AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE NUCLEIC ACIDS

Resumen de: US20260263375A1

The disclosure provides lipid nanoparticle compositions comprising nucleic acids encoding RSV antigenic polypeptides. The present disclosure also provides novel antigenic RSV-F polypeptides as well as nucleic acids encoding the antigenic RSV-F polypeptides.

THERAPEUTIC DELIVERY VECTORS COMPRISING AMPHIPHILIC BLOCK COPOLYMERS

Resumen de: US20260263376A1

A nanoparticle for encapsulation of one or more active pharmaceutical ingredient, said nanoparticle comprising an amphiphilic block copolymer, wherein said amphiphilic block copolymer comprises: i. a hydrophobic polymer block comprising structural units of trimethylene carbonate; and ii. a hydrophilic polymer block comprising structural units of one or more alkylene glycols. A drug delivery vector comprising one or more active pharmaceutical ingredients encapsulated within said nanoparticle. A process for preparing said nanoparticle, the process comprising: i. dissolving said amphiphilic block copolymer in an oligomeric alkylene glycol solution to prepare an alkylene glycol-polymer solution; and ii. hydrating said alkylene glycol-polymer solution by addition of water, an aqueous solution or an aqueous buffer to prepare said nanoparticle. A process for preparing said drug delivery vector by encapsulating one or more active pharmaceutical ingredients within a nanoparticle, wherein said process comprises: i. co-dissolving said amphiphilic block copolymer and said one or more active pharmaceutical ingredients in an oligomeric alkylene glycol solution to prepare an alkylene glycol-polymer solution; and ii. hydrating said alkylene glycol-polymer solution by the addition of water, an aqueous solution or an aqueous buffer to prepare said drug delivery vector. Said drug delivery vector for use as a medicament, preferably for use in the treatment of cancer.

TREG THERAPY

Resumen de: US20260263556A1

The present invention relates to a lipid nanoparticle comprising mRNA encoding FOXP3 and at least a second polypeptide, wherein said lipid nanoparticle comprises a moiety capable of specifically binding to a molecule expressed on a CD4+ T cell and wherein said mRNA is modified to have increased stability as compared to unmodified mRNA.

PROGRAMMABLE DRUG-DEVICE MICRONEEDLE SYSTEM FOR THE DELIVERY AND MONITORING OF DIABETES AND OBESITY MEDICATIONS

Resumen de: US20260263353A1

This invention relates to drug-device core-shell microneedle devices containing anti-diabetes and anti-obesity medications, and transdermal delivery of said medications. The microneedle drug-device system comprises: (a) a two-dimensional array of conical bilayer containing an inner layer with the base diameter ranging from about 100 μm to about 500 μm and the height ranging from about 100 μm about 1200 μm capable of accommodating a known amount of anti-diabetes and/or anti-obesity medications, and a suitable, photostable chromophore or a fluorophore whose absorption and/or emission occurring in the range of 400-900 nm; (b) a larger outer layer that adheres to and encapsulates the inner layer, and protects the inner layer, and (c) a two-dimensional array of cylindrical ‘cap layer’ that aligns with and adheres to the basal surface of core shell bilayer and seals the bilayer to prevent leakage of said medication(s). The apical (i.e., sharp) ends of the conical bilayer array inserts into the skin and are programmed to allow the said medications to effuse out of the bilayer and into the skin in a controlled fashion and to be monitored by photodetection devices.

BIODISSOLVABLE MICRONEEDLE ARRAY-METAL-ORGANIC FRAMEWORK-VACCINE BIOCOMPOSITES FOR EFFECTIVE SKIN IMMUNIZATION AND MANUFACTURING THEREOF

Resumen de: US20260263354A1

Disclosed herein are aspects of a microneedle array comprising a metal-organic framework (MOF)-vaccine biocomposite and methods for using the same. The microneedle array further comprises a dissolvable material that dissolved when inserted into the skin of a subject, thereby releasing the MOF-vaccine biocomposite. The MOF may be selected to dissolve in an acidic environment, thereby targeting the vaccine delivery to specific cellular compartments. Methods for making the MOF-vaccine biocomposite and the microneedle array also are disclosed.

NANOBODY FOR NOROVIRUS

Resumen de: US20260265349A1

The present disclosure relates to the field of nanobodies, therapeutic agents, compositions and methods for the prevention, amelioration and treatment of noroviral infections.

MIXED NANO-LIPID DELIVERY SYSTEM FOR mRNA, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: US20260263633A1

Disclosed are a mixed nano-lipid delivery system for mRNA, and a preparation method therefor and a use thereof. The delivery system is composed of an anionic and cationic mixed lipid, PEG2000-DSPE, a buffer system and mRNA; the anionic and cationic mixed lipid is composed of anionic nucleoside phospholipid TPS or CPS and cationic peptide lipid CLD or CLDA; and the buffer system is a PBS or Opti-MEM™ buffer system containing Ca2+ having a concentration 0.1 mM. The delivery system can efficiently deliver mRNA into cells and mice, and can realize long-time stable expression of proteins in vivo. In addition, an HPV E7 mRNA vaccine provided by the present disclosure can successfully activate humoral and cellular immunity in mice, reduce the mortality rate of HPV-related cervical cancer mice, and have good safety.

CARRIER MATERIAL FOR LOCALLY RELEASING PARTICULATE SUBSTANCE

Resumen de: US20260263631A1

An object of the present invention is to provide a biocompatible carrier material capable of locally releasing particles.The present inventors have found that by using a non-gelling polymer formed by reversibly bonding a plurality of hydrophilic polymer units as a carrier material, it is possible to locally release particles to an affected part such as an ulcer surface, thereby enhancing gene transduction specificity and reducing off-target effects.

COMPOSITIONS OF NANOPARTICLES FOR TREATMENT OF NEUROPATHIC PAIN

Resumen de: US20260263374A1

The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns nanoparticles and/or aggregates of nanoparticles, a composition comprising said nanoparticles and/or aggregates of nanoparticles, and their use in the treatment of NP.

Targeted Nanomedicine for Treating Arterial Disease

Resumen de: US20260263569A1

This disclosure relates to lipid nanoparticle composition comprising polyamidoamine (PAMAM) dendrimer (G0-C14), cholesterol, polyethylene glycol 2000 (PEG), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly(ethylene glycol) (DSPE-PEG), dioleoylphospha-tidylethanolamine (DOPE), and PLPP3 mRNA encapsulated by the lipid nanoparticle, and methods for treating arterial disease, including, for example, atherosclerosis, peripheral artery disease, ischemic stroke, and stenosis.

Targeted Nanomedicine for Treating Lung Disorders

Resumen de: US20260263627A1

This disclosure relates to compositions and methods for treating lung disorders, including, for example, Acute Respiratory Distress Syndrome (ARDS), Ventila-tor-Induced Lung Injury (VILI), Acute lung injury (ALI), and other acute and chronic lung disorders. Further, wherein a lipid nanoparticle, comprises: a) a VCAM-1 targeting molecule; and b) an RNA molecule encoding Kriippel-like Factor 2 (KLF2).

A LYOPHILIZED RNA COMPOSITION

Resumen de: US20260263371A1

The invention is situated in the field of RNA formulation, in particular to lyophilization of RNA. More specifically, the invention relates to a composition that is lyophilized and a method to obtain a lyophilized composition. Moreover, the present invention provides the use of a reconstituted composition according to the invention in human and/or veterinary medicine.

UNIVERSAL INFLUENZA MRNA VACCINE AND USE THEREOF

Resumen de: US20260263585A1

A universal influenza mRNA vaccine is used to encode a protein. The resulting protein encoded by the universal influenza mRNA vaccine has a matrix protein 2 extracellular domain (M2e), a hemagglutinin (HA) stem LAH region and a nucleoprotein (NP) of an influenza A virus. The universal influenza mRNA vaccine is used in a mouse animal model. The universal influenza mRNA vaccine can induce strong humoral immune and cellular immune responses, and can protect animal model mice against various influenza A viruses.

Tumor Immunotherapy

Resumen de: US20260263573A1

Disclosed is a composition comprising a closed-loop peptide comprising at least two methionines and at least two sulfonium centers; and a conjugate of a negatively charged immunoadjuvant and a peptide.

MRNA THERAPEUTIC COMPOSITIONS

Resumen de: US20260263575A1

Disclosed herein are mRNA therapeutic compositions including one or more polynucleotides encoding one or more tumor antigenic, immunogenic, or signaling polypeptides, formulated within a lipid reconstructed plant messenger packs (LPMPs) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making a mRNA therapeutic composition, comprising reconstituting a film comprising purified PMP lipids in the presence of an ionizable lipid to produce a LPMP comprising the ionizable lipid, and loading into the LPMPs with one or more polynucleotides encoding one or more tumor antigenic or immunogenic polypeptides.

EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR PREPARATION, AND USES

Resumen de: AU2026220199A1

Abstract Provided are compositions containing extracellular vesicles from microalgae (MEVs) that are exogenously loaded with bioactive cargo or other cargo of interest, such as for therapeutic, industrial, diagnostic, and cosmetic uses. The MEVs have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as diagnostics, and other such uses Abstract

METHODS AND COMPOSITIONS FOR TREATING CANCER USING EXOSOMES-ASSOCIATED GENE EDITING

Resumen de: US20260263369A1

Provided herein are compositions comprising exosomes comprising CD47 on their surface, and further comprising a CRISPR system. Further provided are methods of using the exosomes for gene editing and the treatment of cancer by gene editing.

IRON-OXIDE NANOPARTICLE-LOADED MESENCHYMAL STEM CELLS AND USES THEREOF

Resumen de: AU2024432366A1

A composition that includes a stem cell and a coated iron oxide nanoparticle. The coated iron oxide nanoparticle, being present in the cytoplasm of the stem cell, contains a superparamagnetic iron oxide core that is coated with one or more biocompatible polymers, each of which has a polyethylene glycol group, a silane group, and a linker covalently linking the polyethylene glycol group and the silane group. Also provided is a method for treating an inflammatory disorder in which stem cells are cultured in the presence of coated iron oxide nanoparticles and the cultured stem cells are administered to a subject suffering from an inflammatory disorder. Further disclosed is a method for tracking stem cells in vivo by labeling stem cells with coated iron oxide nanoparticles, administering the labeled stem cell to an individual, and obtaining one or more T2 weighted magnetic resonance images of the individual to track the stem cells.

SYNTHESIS AND APPLICATION OF MAGNETIC PARTICLE CONJUGATES FOR THE EXTRACORPOREAL REMOVAL OF ANTIBODIES TARGETING VIRAL VECTORS TO FACILITATE GENE THERAPY

Resumen de: WO2025215034A1

The present invention provides novel conjugates comprising a magnetic particle and a multitude of viral structures covalently bound to said particle. These conjugates are suited for efficient extracorporeal removal of antibodies from blood. In particular, the conjugates are suited as adjuvant treatment in gene therapy.

EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON ADMINISTRATION, AND USES

Resumen de: EP4803075A1

0001 Provided are compositions and drug delivery systems containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo. The MEVs are formulated and administered by a variety of routes of administration and have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as therapeutics for psychiatric diseases, disorders, and conditions as diagnostics, and other such uses.

METHOD FOR PREPARING STABLE PEPTIDE NANOPARTICLE FORMULATIONS

Resumen de: WO2025096329A1

The present disclosure is directed to methods of preparing peptide nanoparticle formulations, and in particular, peptide nanosuspensions, using low shear milling. More specifically, the disclosure is directed to methods of preparing peptide nanosuspensions by applying low frequency acoustic energy to an admixture comprising a peptide, an aqueous dispersion medium comprising a surface-active polymer and optionally a surfactant, and milling media, until the peptide has been milled to nanoparticle size. Also described are stable peptide nanosuspensions prepared by the methods.

PH-CONTROLLED BIODEGRADABLE POLYMERIC PARTICLES FOR SUSTAINED RELEASE OF POSITIVELY CHARGED SPECIES

Resumen de: WO2025096848A1

The disclosure relates to microparticles and nanoparticles comprising a porous polymer matrix comprising an uncapped polymer for sustained delivery of a net positively charged therapeutic agent. More particularly the disclosure relates to particles comprising PLGA or PLA which have a first state with relatively more interconnected pores at a first pH and a second state with relatively less interconnected pores at a second pH. Methods of making the particles and administering the particles are also provided.

RNA-SN-38 CONJUGATE FOR THE TREATMENT OF COLORECTAL CANCER AND SEQUENTIAL LUNG METASTASIS

Resumen de: WO2025097049A1

Disclosed herein are compositions and methods for CMC production of RNA therapeutic complexes (nanostructures) that contain SN-38 (7-Ethyl-10-hydroxycamptothecin) and/or Irinotecan. In particular, disclosed herein is an RNA nanoparticle having at least three synthetic RNA nucleotides coupled to each other, wherein the at least three synthetic RNA oligonucleotides form a central ore domain and at least three double-stranded arms arranged around the core domain and extending away from the central core domain, wherein at least one of the three double-stranded arms is conjugated with Irinotecan and/or SN-38 with an esterbond that is cleavable by esterase in cancer tissue or cancer cells.

TARGETED LNP DELIVERY

Resumen de: WO2025096824A1

Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3/antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.

MULTIVALENT INFLUENZA MRNA VACCINE

Resumen de: EP4803629A1

0001 Provided is an isolated mRNA molecule, including a nucleotide sequence encoding a chimeric immunogenic polypeptide, where the chimeric immunogenic polypeptide includes an immunogenic fragment of hemagglutinin HA of influenza A H5N1, an immunogenic fragment of hemagglutinin HA of influenza A H1N1, and an immunogenic fragment of hemagglutinin HA of influenza B Victoria linked together. Further provided are a composition and a vaccine including the mRNA, a fusion protein encoded by the mRNA, and a method for inducing an immune response against an influenza virus in a subject using the mRNA, the composition, the vaccine, and the fusion protein.

IMMUNOGENIC COMPOSITION OF AFRICAN SWINE FEVER VIRUS CD2V PROTEIN AND USE THEREOF

Resumen de: EP4803532A1

An immunogenic fragment of African swine fever virus CD2V protein, a recombinant protein, an immunogenic composition, and a use thereof. The provided immunogenic fragment of African swine fever virus CD2V protein or a variant thereof with immunogenicity can greatly improve the expression quantity while retaining the strong immunocompetence.

COMPOSITIONS TARGETING KLKB1 AND METHODS OF USE THEREOF

Resumen de: WO2025096980A1

Disclosed are methods and compositions for functional genetic modifications at selected genomic sites such as KLKB1 gene. Also provided are cell populations, which comprise the functional genetic modification at one or more selected gene loci.

GLYCOENGINEERED EXTRACELLULAR VESICLES, METHODS OF PRODUCTION AND USES THEREOF

Resumen de: WO2025093745A1

The present invention relates to glycoengineered extracellular vesicles, as well as methods of production of such glycoengineered extracellular vesicles, methods of glycoengineering extracellular vesicles, and uses of glycoengineered extracellular vesicles.

LIPIDS AND LIPID NANOPARTICLE FORMULATIONS

Resumen de: WO2025091377A1

The present disclosure relates generally to lipids, lipid nanoparticle formulations, and methods of using the same for delivering nucleic acids, such as mRNA.

RNA FOR IN VIVO TRANSFECTION WITH INCREASED EXPRESSION

Resumen de: US20250144234A1

0000 This disclosure provides improved RNA molecules, including mRNA molecules that can be produced by in vitro transcription and are suitable for in vivo transfection using an appropriate delivery vehicle, such as a lipid nanoparticle (LNP) or targeted lipid nanoparticle (tLNP). The improved RNA include particular combinations of 5′ untranslated region (UTR) and 3′ UTR, particular 3′ UTRs, or particular open reading frame sequences. Also provided herein are compositions of the LNP, or tLNP with an antibody as a targeting moiety, such as anti-CD8 antibodies that are used as targeting moiety.

LIPID COMPOUNDS

Resumen de: WO2025096940A1

The present invention relates to lipids that include novel triazole, and alkyl- and alkene-substituted amine compounds, intermediates in their synthesis, and uses of such triazole, and alkyl- and alkene-substituted amine compounds in, for example, lipid nanoparticle compositions for drug delivery and cancer treatments.

PARTICLES, COMPOSITIONS AND METHODS

Resumen de: WO2025093665A1

The present disclosure relates generally to functionalized particles containing moieties capable of binding Immunoglobulin D (IgD), methods for producing them, and to pharmaceutical compositions containing them and their uses in medicine.

NOVEL GENE DELIVERY AGENTS

Resumen de: US20250144233A1

0000 Nanoparticle compositions for delivery of nucleic acids to subjects including aminoalkyl branched lipid-like molecules as carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the nanoparticle containing are described. Also provided are methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects.

3'-UTR WITH IMPROVED TRANSLATION EFFICIENCY, A SYNTHETIC NUCLEIC ACID MOLECULE COMPRISING THE SAME, AND A VACCINE OR THERAPEUTIC COMPOSITION COMPRISING THE SAME

Resumen de: WO2025095526A1

The present invention relates to a synthetic nucleic acid molecule comprising 3'-UTR polynucleotide with improved translation efficiency and a vaccine composition comprising the same, and more particularly to a synthetic nucleic acid molecule comprising 3'-UTR with improved translation efficiency manufactured by inclusion of specific motif and a codon-optimized signal sequence and an antigen encoding sequence, and a vaccine composition comprising the same. The synthetic nucleic acid molecule according to the present invention comprises a 3'-UTR polynucleotide with improved translation efficiency, which can effectively induce the expression of an antigenic polypeptide, which is useful for vaccine development because it can be expected to increase immunogenicity as a vaccine.

NANOPARTICLE VACCINE FOR PREVENTING MYCOBACTERIUM TUBERCULOSIS INFECTION AND PREPARATION METHOD THEREFOR

Resumen de: EP4803097A1

0001 Disclosed is a Mycobacterium tuberculosis vaccine. Specifically, the vaccine comprises an immune composition comprising an antigen component and a particulate protein component. The particulate protein component comprises nanoparticle protein. The antigen component and the particulate protein component are covalently bound by means of a binding peptide 1 and a binding peptide 2 to form an immunogenic complex. The vaccine has excellent cell immunogenicity and antibody immunogenicity. The present invention also relates to a preparation method for the mycobacterium tuberculosis vaccine.

THERAPEUTIC AGENT FOR METABOLIC DISEASES COMPRISING DELIVERY SYSTEM BASED ON METAL NANOPARTICLE-NUCLEIC ACID CONJUGATE

Resumen de: EP4803104A1

0001 The present invention relates to a use, as a drug delivery vehicle, of a gene carrier comprising a metal nanoparticle and a double-stranded nucleic acid molecule bound to a surface of the metal nanoparticle, in particular to a use of the carrier for the treatment of a metabolic disease, and to a pharmaceutical composition for the prevention or treatment of a metabolic disease comprising the same.

mRNA初免疫苗组合物及其使用方法

Resumen de: WO2025160594A1

A method for immunizing a subject against a pathogen, comprising the steps of: (1) administering to the subject an effective amount of a prime vaccine, wherein the prime vaccine comprises one or more mRNA constructs encoding one or more immunogens from the pathogen; and (2) administering to the subject an effective amount of a boost vaccine, wherein the booster vaccine comprises a non-mRNA vaccine modality, such as a recombinant protein, against the pathogen, wherein the boost vaccine comprises the immunogen or immunogens encoded in one or more mRNA constructs in the prime vaccine, or wherein the boost vaccine comprises the immunogen or immunogens that are not the same as encoded in one or more mRNA constructs in the prime vaccine, wherein the boost vaccine is administered after the administration of the prime vaccine.

一种可电离阳离子脂质化合物及其制备方法和应用

Resumen de: CN117986153A

The invention provides an ionizable cationic lipid compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ionizable cationic lipid compound provided by the invention is a compound with a formula (1), or a salt, a stereoisomer and a tautomer thereof, can be used as a surfactant in various fields, and especially can be used as a lipid composition for delivering a therapeutic agent. The prepared lipid nanoparticles can show good effectiveness and safety in cells and in animal bodies. # imgabs0 #

一种靶向modABC调控铁代谢的联合抗菌剂及其制备方法

Resumen de: CN122701876A

本申请公开了一种靶向modABC调控铁代谢的联合抗菌剂及其制备方法，属于抗感染药物技术领域。该联合抗菌剂中铁螯合剂与modABC通路抑制剂的质量比为1:0.5‑2，通过铁螯合剂与modABC通路抑制剂的协同作用，双重阻断细菌铁摄取途径，避免细菌产生代偿性铁摄取机制，实现高效杀菌；同时本申请提供联合抗菌剂的制备方法包括原料预处理、分散体系制备、乳化反应、载体成型、纯化处理、制剂后处理六个核心步骤，可根据实际制备需求，选择合适的分散介质、乳化参数、载体成型方法及功能辅料，实现联合抗菌剂的高效制备。

一种用于治疗和改善日光性皮炎的汉黄芩素立方液晶纳米粒水凝胶的制备方法及其应用

Resumen de: CN122701648A

本发明公开了一种用于治疗和改善日光性皮炎的汉黄芩素立方液晶纳米粒水凝胶的制备及其应用。本发明制备方法是先将汉黄芩素与GMO和F127制备成汉黄芩素立方液晶纳米粒，再加入羟苯甲酯、甘油、壳聚糖和乳酸制备成汉黄芩素立方液晶纳米粒水凝胶。该汉黄芩素立方液晶纳米粒水凝胶可用于治疗和改善日光性皮炎，且起效更快，外透皮能力强，能提供更久的药物渗透能力。

白藜芦醇-单形拟杆菌共封装微胶囊组合物、制备方法及其应用

Resumen de: CN122701682A

本发明公开了一种白藜芦醇‑单形拟杆菌共封装微胶囊组合物、制备方法及其应用。属于微胶囊技术领域。针对疏水性多酚白藜芦醇稳定性差、单形拟杆菌在加工和消化道中易失活，以及现有技术难以将二者同步保护与递送的问题，本发明提供了一种以乳清分离蛋白、壳聚糖和果胶为壁材的多层复合微胶囊。该微胶囊利用乳清分离蛋白的疏水结构域包埋白藜芦醇形成蛋白核心，再依次包覆壳聚糖阳离子层和果胶外壳层，并将单形拟杆菌包埋于外层多糖屏障中。通过选择不同酯化度的果胶可调控外壳致密程度，实现胃液保护与肠液释放的平衡。本发明能够显著提高白藜芦醇的稳定性以及单形拟杆菌在包埋、贮藏、热处理和模拟胃液中的存活率。

一种细胞膜包覆氧缺陷氧化铜纳米声敏剂及其制备方法和应用

Resumen de: CN122701685A

本发明公开了一种细胞膜包覆氧缺陷氧化铜纳米声敏剂及其制备方法和应用，属于纳米生物医药与肿瘤声动力治疗技术领域。该纳米声敏剂为核壳结构，内核为富含氧空位缺陷的氧化铜（CuO1‑X）纳米颗粒，作为超声响应声敏单元；外壳为肿瘤细胞膜融合层，赋予制剂同源靶向与生物相容性。通过氧空位缺陷工程调控氧化铜电子结构，显著提升超声辐照下活性氧生成效率；在超声刺激下，该制剂可同步实现三重协同抗肿瘤效应：一是活性氧介导的声动力直接杀伤肿瘤细胞，二是下调 CXCR4‑CXCL12 信号轴抑制肿瘤转移，三是诱导免疫原性细胞死亡激活全身性抗肿瘤免疫。体内外实验证实，该制剂对三阴性乳腺癌原位生长及肺转移具有显著抑制效果。

一种兔出血症病毒的mRNA、疫苗及其制备方法与应用

Resumen de: CN122706715A

本发明提供了一种兔出血症病毒的mRNA、疫苗及其制备方法与应用，属于基因工程技术领域。本发明提供的兔出血症病毒的mRNA，在抗原编码区的5'端添加N7mGpppAm帽结构和5'UTR，在抗原编码区的3'端添加3'UTR与poly(A)尾；所述抗原编码区包括核苷酸序列如SEQ ID NO.1所示的RHDV1抗原编码区或核苷酸序列如SEQ ID NO.2所示的RHDV2抗原编码区。本发明提供的兔出血症病毒的mRNA疫苗，能够在机体内有效地翻译成抗原蛋白，可诱导产生针对RHDV1、RHDV2的高水平抗体，对RHDV1、RHDV2的流行分离毒株具有良好的保护性，为RHDV的防控提供了新型技术和产品支撑。

一种负载雷公藤甲素的氮氧自由基聚合物纳米颗粒及其制备方法和在小细胞肺癌中的应用

Resumen de: CN122701686A

本发明提供了一种负载雷公藤甲素的氮氧自由基聚合物纳米颗粒及其制备方法和在小细胞肺癌中的应用，属于纳米医药技术领域。本发明提供的纳米颗粒采用氮氧自由基聚合物作为载体，其氮氧自由基结构不仅赋予了纳米颗粒良好的稳定性和生物相容性，还能让雷公藤甲素（TP）在体内进行长循环，主要蓄积在肿瘤部位，从而主动降低TP引起的氧化应激损伤，纳米颗粒在体外能有效抑制人源或鼠源小细胞肺癌细胞活力，在皮下移植瘤和原位瘤模型中表现出优于游离TP的抗肿瘤效果，而且能显著减轻TP引起的全身毒性，特别是对睾丸组织的损伤，保护雄性生育能力。

一种植物纳米囊泡提取物的制备方法及应用

Resumen de: CN122706582A

本发明属于植物提取技术领域，具体公开了一种植物纳米囊泡提取物的制备方法及应用，将植物原料清洗后进行反复冻融处理；冻融后的原料加入预冷提取缓冲液低温匀浆；匀浆液先低速离心、再高速离心取上清；上清用切向流过滤系统浓缩并洗滤，收截留液；截留液超速离心后取沉淀，用提取缓冲液重悬即得。本发明方法提取的植物纳米囊泡的产率高，植物纳米囊泡提取物纯度高、粒径均一、结构完整，纳米囊泡的平均粒径为80~150 nm，多分散系数小于0.25，囊泡呈典型的茶托状或球状形态，磷脂双分子层结构完整，可用于药物载体、化妆品及功能性食品。

自佐剂纳米颗粒PA0833-mi3的制备及其应用

Resumen de: CN122701849A

本发明提供了一种铜绿假单胞菌抗原PA0833与载体蛋白mi3通过Linker连接可自组装形成纳米颗粒化的PA0833‑mi3重组蛋白。本发明提供了表达载体和重组工程菌，以及在作为铜绿假单胞菌疫苗抗原的应用。本发明还提供了PA0833‑mi3重组蛋白作为抗原时本身具有自佐剂效应。本发明公开了PA0833‑mi3自佐剂纳米颗粒黏膜疫苗的制备及用于诊断、防治或治疗铜绿假单胞菌感染在药物中的应用。采用本发明提供的重组蛋白可有效刺激机体产生较高的体液免疫、细胞免疫和黏膜免疫应答。

粘膜组织靶向阳离子脂质化合物及其在制备药物制剂中的应用

Resumen de: CN122705435A

本申请公开了一种化合物，结构式如式(Ⅰ)所示，以及其药学上可接受的盐或其立体异构体，本申请还公开了一种包含上述化合物或其药学上可接受的盐或其立体异构体的纳米颗粒药物制剂，本申请的纳米颗粒对于粘膜组织有特异性靶向作用，可以高效递送药物、疫苗至细胞内，发挥药物、疫苗的治疗或预防目的。

一种富含MFGE8的鹿茸干细胞外泌体抗肝纤维化药物制剂

Resumen de: CN122701750A

本发明公开了一种富含MFGE8的鹿茸干细胞外泌体抗肝纤维化药物制剂，该药物制剂以鹿茸干细胞外泌体为活性成分，所述鹿茸干细胞外泌体中MFGE8（乳脂球表皮生长因子8）的含量不低于100ng/mg总蛋白。本发明通过特定的培养条件和分离纯化方法，显著提高了鹿茸干细胞（ASCs）外泌体中MFGE8的表达水平，使其能够通过抑制肝星状细胞活化、促进肝细胞修复再生以及调节肝脏免疫微环境等多种途径，有效逆转肝纤维化进程。本发明的药物制剂具有生物相容性好、靶向性强、副作用小等优点，为肝纤维化的临床治疗提供了一种新的有效手段。

一种CuPB@HA纳米药物的制备方法及其应用

Resumen de: CN122701684A

本发明提供了一种透明质酸包覆铜掺杂普鲁士蓝纳米酶CuPB@HA的制备方法及应用。所述制备方法包括以下步骤：首先合成普鲁士蓝纳米颗粒，再掺杂铜得到铜掺杂普鲁士蓝纳米颗粒CuPB，并对其表面进行透明质酸修饰，获得CuPB@HA纳米酶。所述CuPB@HA纳米酶可靶向识别并富集于动脉粥样硬化病灶中CD44高表达的巨噬细胞，从而提高病灶部位摄取效率。该纳米酶兼具脂质代谢调控功能，可降低脂质摄取受体CD36表达，并上调胆固醇外排相关蛋白ABCA1和ABCG1表达，进而减少泡沫细胞形成，促进巨噬细胞向有利于炎症消退的表型转化。与此同时，所述CuPB@HA纳米酶亦具备活性氧清除能力，能够有效缓解斑块微环境中的氧化应激，从而进一步抑制炎症反应，提升斑块稳定性。动物实验表明，所述CuPB@HA纳米酶可显著降低动脉粥样硬化斑块负荷并提高斑块稳定性，具有良好的应用前景。

一种用于治疗缺血性脑卒中的纳米载药系统及其制备方法

Resumen de: CN122701681A

本发明公开一种用于治疗缺血性脑卒中的纳米载药系统及其制备方法；所述纳米载药系统包括脂质纳米颗粒载体、负载的治疗活性物质以及表面修饰的第一靶向分子和第二靶向分子；治疗活性物质包括Zn2+依赖型脱氧核酶和疏水性抗炎药物姜黄素；第一靶向分子介导跨越血脑屏障，第二靶向分子引导靶向至脑缺血病灶；该载药系统利用缺血病灶区域Zn2+浓度显著升高的病理微环境特异性激活脱氧核酶，沉默NLRP3炎症小体基因表达，同时联合姜黄素清除活性氧，实现从早期氧化应激到后期神经炎症的阶段性协同治疗，有效提高脑卒中治疗效果并降低毒副作用。

一种用于子宫内膜癌靶向递送siRNA的铜基仿生纳米药物及其制备方法和应用

Resumen de: CN122701880A

本发明涉及生物医药技术领域，公开了一种用于子宫内膜癌靶向递送siRNA的铜基仿生纳米药物及其制备方法和应用，纳米药物为子宫内膜癌细胞膜包裹的Cu/siRNA复合纳米颗粒，Cu/siRNA复合纳米颗粒由铜离子和siRNA组装而成，同时具备靶向肿瘤递送siRNA和免疫治疗增敏能力，以解决现有子宫内膜癌免疫治疗对肿瘤抗原呈递不足改善程度有限，难以激活充分且持久的抗肿瘤免疫应答，进而导致临床获益受限的问题。

一种靶向巨噬细胞的纳米颗粒及其制备方法和应用

Resumen de: CN120732817A

The invention discloses macrophage targeting nanoparticles as well as a preparation method and application thereof, belongs to the technical field of biomedicine, and solves the technical problems of poor macrophage targeting, short joint residence time, poor inflammation regulation effect and the like in current osteoarthritis treatment in the prior art. The nano-particles of the targeted macrophage are nano-particles of which the surfaces are modified with PGlu, the general formula is P1-b-PGlu, P1 is a hydrophobic segment polymer, or the nano-particles which can enter a living body and are non-toxic, specifically, by introducing a glucosamine functional group, the combination of the nano-particles and a saccharide recognition receptor on the surface of a macrophage cell membrane is enhanced, and the macrophage recognition efficiency is improved. Therefore, the active targeting on the macrophages is realized. The constructed nano-particles have excellent physical stability and appropriate particle size distribution, the residence time of the nano-particles in an articular cavity is remarkably prolonged, and continuous slow release is achieved. The targeted nano system effectively realizes polarization conversion from M1 to M2, improves a synovial immune microenvironment, and plays a synergistic treatment role of immune regulation and tissue repair.

ATP响应性脂质、核酸纳米制剂和制备方法

Resumen de: CN122705483A

本发明涉及一种ATP响应性脂质、核酸纳米制剂和制备方法。该ATP响应性脂质的结构式如下式(I)所示。本发明的ATP响应性脂质以及核酸纳米制剂在细胞内高水平ATP条件下，能够与ATP结合，增加膜的流动性，促进脂质纳米粒与内体膜的融合，破坏内体膜的完整性，增加溶酶体逃逸效率，进而提高核酸递送和表达效率。

一种靶向软骨细胞的代谢重编程水凝胶系统及其制备方法与应用

Resumen de: CN122701651A

本发明涉及生物医用材料技术领域和骨关节炎治疗技术领域，具体涉及一种靶向软骨细胞的代谢重编程水凝胶系统及其制备方法与应用；制备步骤如下：（1）提取软骨细胞膜与FGF21共挤出制备靶向纳米颗粒；（2）合成普鲁士蓝纳米酶；（3）制备苯硼酸修饰透明质酸，与聚乙烯醇构建ROS响应型水凝胶基质；（4）将两种功能纳米颗粒负载于水凝胶前驱液中，交联得到复合水凝胶系统。本发明构建的水凝胶系统兼具软骨细胞同源靶向、ROS响应按需释放、炎症微环境重塑与细胞代谢重编程多重功能，可显著延长FGF21关节腔滞留时间、提升靶向富集效率，协同恢复软骨细胞精氨酸代谢稳态、修复软骨损伤、改善关节功能，生物相容性优异。

一种纳米融合膜疫苗在抗结核分枝杆菌感染中的应用

Resumen de: CN122701847A

本发明属于生物医药技术领域，具体涉及一种纳米融合膜疫苗在抗结核分枝杆菌感染中的应用，为含有纳米融合膜疫苗的药物或药物组合物在抗结核分枝杆菌感染中的应用，纳米融合膜疫苗的制备步骤为：制备结核分枝杆菌菌膜组分；制备大肠杆菌菌膜组分；制备PLGA聚合物纳米颗粒；制备结核病纳米融合疫苗。本发明基于严格的控制变量方法利用溶菌酶去除MTB细胞壁，并提取菌膜组分，将其以设定的比例与大肠杆菌菌膜融合后，通过纳米技术制备出的新型结核病纳米融合膜疫苗开展细胞和动物实验，发现该疫苗体外能够显著提高树突状细胞的成熟并刺激其产生细胞因子。

用于递送的五组分脂质纳米颗粒

Resumen de: CN122701683A

本申请公开了一种脂质纳米颗粒，其包含式(I)所示化合物、阳离子脂质、磷脂、结构脂质和PEG脂质。本申请脂质纳米颗粒相较于传统的四组分脂质纳米颗粒可以更高效地将活性成分递送至细胞内，发挥治疗或预防目的。(I)

基于苹果酸和戊二酸的可电离脂质

Resumen de: WO2025134071A1

Provided herein are ionizable or cationic lipids of Formula (I): (I), or pharmaceutically acceptable salts thereof. The ionizable or cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

工程化外泌体模拟脂质纳米颗粒及其制备方法和在制备促进老年肝脏再生的药物方面的应用

Resumen de: CN122681820A

本发明公开了工程化外泌体模拟脂质纳米颗粒及其制备方法和在制备促进老年肝脏再生的药物方面的应用。所述的工程化外泌体模拟脂质纳米颗粒包含作为载体的脂质体及其负载的蛋白质和miRNA；所述的miRNA包含hsa‑miR‑222‑3p、hsa‑miR‑221‑3p和hsa‑miR‑7‑5p，所述的蛋白质包含PGD、C3、COL1A1、AHCY、A2M、APOB和GLUL。其专门用于逆转肝脏衰老并恢复老年肝脏组织的结构与功能完整性。

リピドイド化合物ならびに関連する組成物および使用

Resumen de: WO2025049925A2

The present disclosure provides compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications.

一种含有氨基甲酸酯的阳离子脂质、包含其的组合物及用途

Resumen de: CN122685538A

本发明公开了一种含有氨基甲酸酯的阳离子脂质、包含其的组合物及用途，具体公开了一种式(I)所示的阳离子脂质。本发明提供的阳离子脂质能特异性地递送药物到特定的细胞，同时可显著降低细胞毒性，有助于发挥药物的疗效，能够提升药物在体内的靶向递送效率和安全性。

一种透明质酸、L-精氨酸包覆复合纳米粒子及其制备方法

Resumen de: CN122681823A

本发明公开了一种透明质酸、L‑精氨酸包覆复合纳米粒子及其制备方法，涉及医药技术领域；该复合纳米粒子以β‑环糊精包载伏立诺他（SAHA）形成纳米粒子，外层包覆氧化透明质酸（OHA）和L‑精氨酸（L‑Arg）；制备过程中，先通过透析法制得纳米粒子，再依次加入OHA和L‑Arg进行避光反应，最终得到CS@OL复合纳米粒子；该粒子平均粒径为87nm，在室温下21天内保持稳定。本发明复合纳米粒子具有良好的自由基清除能力、细胞相容性、跨内皮递送能力及靶向炎症细胞的能力，能够协同递送SAHA和L‑Arg，调节ROS/NO稳态，抑制炎症反应，适用于动脉粥样硬化等氧化应激相关疾病的治疗。

一种用于特异性检测tRNA来源小片段RNA 5-GlyTCC-L33表达水平的试剂及其模拟物的应用和试剂盒

Resumen de: CN122686807A

本发明涉及生物医药技术领域，具体涉及用于特异性检测tRNA来源小片段RNA 5‑GlyTCC‑L33表达水平的试剂在制备用于胎儿生长受限辅助评估产品中的应用，5‑GlyTCC‑L33模拟物在制备用于胎儿生长受限实验动物模型构建的模型诱导试剂或模型诱导组合物中的应用，以及相关试剂盒；本发明通过对正常妊娠与胎儿生长受限胎盘组织进行小RNA测序分析，发现5‑GlyTCC‑L33在胎儿生长受限胎盘组织中显著上调，通过检测离体胎盘绒毛膜组织样本中5‑GlyTCC‑L33的表达水平，并与正常妊娠对照水平或预设参考阈值比较，可生成体外检测结果或辅助判读信息可作为胎儿生长受限辅助评估的候选分子标志物。

一种纳米材料Q-MNPS及其制备方法和在脑缺血神经保护中的制药新用途

Resumen de: CN122681817A

本发明公开了一种纳米材料Q‑MNPS及其制备方法和在脑缺血神经保护中的制药新用途，涉及生物医药技术领域。包括：金属‑药物配位聚合物内核；包覆所述内核的天然细胞膜外壳；其中，所述金属‑药物配位聚合物内核在活性氧环境下发生解离，释放药物分子；所述天然细胞膜外壳赋予所述纳米颗粒穿透血脑屏障的能力。本发明通过天然细胞膜外壳的生物伪装特性实现血脑屏障穿透，利用金属‑药物配位聚合物内核的活性氧响应性在缺血病灶定点释放药物，具有优异的神经保护作用，能够显著改善神经功能缺损并降低死亡率。

负载二烯丙基三硫化物的长双歧杆菌来源细胞外囊泡纳米复合物及其制备方法、应用

Resumen de: CN122681819A

本发明公开一种负载二烯丙基三硫化物的长双歧杆菌来源细胞外囊泡纳米复合物，包括：长双歧杆菌来源细胞外囊泡（BL‑EVs），以及负载于BL‑EVs中的二烯丙基三硫化物（DATS）；纳米复合物是通过将BL‑EVs与DATS混合后进行共挤出及孵育处理制得的、具有单分散囊泡结构的纳米复合物实体。本发明的纳米复合物具备细胞内微环境刺激响应性，在被牙周相关细胞摄取进入胞内后，特异性响应于胞内谷胱甘肽微环境触发内部有机硫键断裂，并在胞内靶向缓释硫化氢，用以通过上调靶细胞抗氧化保护蛋白的表达与活性以产生抗氧化增效作用，并在此基础上，协同诱导巨噬细胞向抗炎修复型M2巨噬细胞重塑，同时上调牙龈成纤维细胞抗铁死亡保护蛋白的表达与活性以阻断其铁死亡进程。

一种用于椎间盘退变修复的聚多巴胺修饰ZnO/BaTiO3异质结复合材料及其制备方法

Resumen de: CN122682090A

本发明公开了一种用于椎间盘退变修复的聚多巴胺修饰ZnO/BaTiO3异质结复合材料及其制备方法，属于生物医用材料技术领域。该材料以四方相钛酸钡为核心、表面原位生长氧化锌构建II型异质结，并包覆聚多巴胺功能层。制备时，先水热法制备钛酸钡，再经溶剂蒸发与高温煅烧引入氧化锌，最后在多巴胺溶液中自聚包覆。本发明利用超声驱动异质结产生声电耦合效应，II型异质结促进载流子分离以提升压电催化活性，PDA涂层清除活性氧、缓解炎症。体外实验证实该材料促进髓核细胞基质合成、抑制炎症，动物实验验证其延缓椎间盘退变。本发明通过“声电转化‑电荷分离‑电刺激‑环境重塑”一体化设计，为深部组织修复提供了高效无创策略。

一种核酸药物选择性递送的膦酯化可电离脂质及其制备方法与应用

Resumen de: CN122685654A

本发明属于生物医药的技术领域，公开了一种核酸药物选择性递送的膦酯化可电离脂质及其制备方法与应用。所述膦酯化可电离脂质其结构通式为式I，式I中Cn为含有膦酯的结构，Nn为含氮的环状结构或含氮的胺基基团，B为O或NH；Ln作为连接键。本发明还公开了膦酯化可电离脂质的制备方法。本发明的膦酯化可电离脂质用于制备膦酯化可电离脂质纳米颗粒，作为核酸药物选择性递送至心、肺脏、脾脏、肝脏和/或肌肉递送载体。本发明的可电离脂质协同整合了膜稳定性与内涵体逃逸功能，有效规避传统靶向修饰中存在的蛋白冠屏蔽效应，能够将核酸药物高效、安全地递送至肝外器官，特别是肺和脾。式I：。

类脂质化合物及相关组合物和用途

Resumen de: WO2025171237A1

Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.

靶向多发性骨髓瘤细胞的细胞膜材料及其应用

Resumen de: CN122681818A

本发明属于生物医药技术领域，具体涉及一种靶向多发性骨髓瘤细胞的细胞膜材料及其制备方法和应用。本发明要解决的技术问题是骨髓瘤细胞治疗药物缺乏足够的跨骨髓屏障递送和肿瘤靶向性，且易造成全身性毒副作用。本发明解决技术问题的技术方案是提供了一种靶向多发性骨髓瘤细胞的细胞膜材料。该膜材料为表面表达有抗GPRC5D的抗体的细胞的细胞膜。本发明细胞膜材料继承有膜源细胞“骨髓归巢”效应增强药物的跨骨髓屏障递送，并对多发性骨髓瘤细胞表面GPRC5D配体有主动靶向结合能力，可实现高效递送药物至骨髓腔内的肿瘤部位并高效摄取入多发性骨髓瘤细胞，进而实现药物在骨髓病灶处的精准富集与释放，从而提高治疗效果，降低全身毒性，为多发性骨髓瘤的治疗提供了一种有效的药物载体方案。

脂质化合物和脂质纳米颗粒组合物

Resumen de: CN122685532A

本文提供一种脂质化合物，其可与其他脂质成分(例如中性脂质、胆固醇和聚合物结合脂质)组合使用，以形成脂质纳米颗粒，用于递送治疗剂(例如核酸分子)以用于治疗或预防目的。本文还提供包含式I所示脂质化合物的脂质纳米颗粒组合物。

一种基于花瓣形MnO2纳米复合材料、制备方法及应用

Resumen de: CN122681824A

本发明涉及生物材料技术领域，公开了一种基于花瓣形MnO2纳米复合材料、制备方法及应用，步骤1：高锰酸钾溶液中加入油酸钠，充分反应，得到MnO2；步骤2：MnO2溶液中加入氯铂酸，充分搅拌后，加入抗坏血酸进行还原反应，经热处理即可得到Pt‑SAC；步骤3：Pt‑SAC分散于氯化钙溶液中，调节pH至碱性，充分反应得到Pt‑SAC@ CaO2；步骤4：将活化后的叶酸滴加入壳聚糖溶液中，充分反应后透析，加入Pt‑SAC@ CaO2，充分反应后即可得到所需纳米复合材料；本发明通过在MnO2纳米花载体上制造氧空位，成功锚定Pt单原子，并进一步负载CaO2与CS‑FA靶向外壳，构建靶向、自供应H2O2和外源性Ca2+的化学动力学治疗‑钙死亡协同纳米平台。

一种中性粒细胞介导的工程化交叉纳米囊泡递送平台及其应用

Resumen de: CN122681816A

本发明公开了一种中性粒细胞介导的工程化交叉纳米囊泡递送平台及其应用，属于生物医药技术领域，该递送平台由外源性胆固醇富集的LNV‑SyBV杂合囊泡及其负载的多粘菌素B组成；外源性胆固醇富集的LNV‑SyBV杂合囊泡由植物来源抗炎囊泡、减毒细菌囊泡、外源性胆固醇制备；植物来源抗炎囊泡为柠檬来源的纳米囊泡LNV；减毒细菌囊泡为大肠杆菌来源的合成囊泡SyBV。本发明一种中性粒细胞介导的工程化交叉纳米囊泡递送平台及其应用，通过靶向递送、抗菌抗炎双重功能及低免疫毒性，为碳青霉烯耐药革兰氏阴性菌感染的临床治疗提供了创新策略。

一种巨噬细胞膜仿生纳米粒靶向SPP1抗肾纤维化药物系统

Resumen de: CN122681822A

本发明涉及生物医药技术领域，且公开了一种巨噬细胞膜仿生纳米粒靶向SPP1抗肾纤维化药物系统，该系统包含PLGA纳米粒内核、能够结合并中和SPP1蛋白活性的抗体以及具有炎症趋化和病灶归巢能力的巨噬细胞膜包裹层，抗体负载于PLGA纳米粒内核表面，巨噬细胞膜包裹层包覆于负载抗体的PLGA纳米粒外表面形成核‑壳结构。制备方法包括滴加法制备PLGA纳米粒、抗体负载、低渗裂解提取巨噬细胞膜、超声和挤出完成膜包裹。该系统利用巨噬细胞膜天然携带的炎症趋化受体实现肾纤维化病灶主动靶向归巢，在肾纤维化模型中能够降低纤维化面积，促进E‑cadherin恢复，延长体内循环时间，提高病灶富集浓度。

一种用于肺高效递送厚朴酚的类脂质纳米递药系统及其制备方法与应用

Resumen de: CN122681821A

本发明公开了一种用于肺部高效递送厚朴酚的类脂质纳米递药系统及其制备方法与应用，由脂质材料4A3‑SC8、1,2‑二油酰基‑3‑三甲基铵‑丙烷、胆固醇、1,2‑二肉豆蔻酰‑rac‑甘油‑3‑甲氧基聚乙二醇2000、1,2‑二油酰基‑sn‑甘油‑3‑磷酸乙醇胺与厚朴酚自组装而成。其优点在于，利用阳离子‑π及疏水作用实现了不带电中药厚朴酚的高效包载，克服了其易结晶、易泄漏的难题；利用内源性电荷屏蔽效应实现高浓度阳离子脂质投入下的低表面电荷，降低了毒性风险。该递药系统经气道局部给药后可在肺部原位构筑抗病毒屏障，并协同抑制冠状病毒NSP12/NSP14复制酶活性，在动物模型中表现出超越一线临床用药的体内保护效果。本发明为中药小分子的肺高效递送及呼吸道抗病毒治疗提供了新的制剂平台。

新規ヒスチジンアミドコレステロール化合物及びそれを含むＲＮＡ送達用脂質ナノ粒子

Resumen de: WO2025048497A1

The present invention relates to a novel histidine amide cholesterol compound and RNA delivery lipid nanoparticles comprising same. The present invention can have improved mRNA delivery efficiency and expression efficiency while having biocompatibility.

C-C基序趋化因子受体作为治疗子宫瘢痕新靶点的应用

Resumen de: CN122681898A

本发明公开了C‑C基序趋化因子受体作为治疗子宫瘢痕新靶点的应用。CCR1作为子宫瘢痕疾病的全新治疗靶点，能够推动子宫瘢痕病变持续进展，通过磷酸化下游Six1、促进细胞外基质生成，进而介导子宫瘢痕产生。通过沉默该受体，可有效阻滞子宫瘢痕的发生与发展，提升女性妊娠成功率，并减少各类不良妊娠结局的出现。本方案的制备工艺为：将可电离脂质、DSPC、胆固醇、DMG‑PEG混合溶解在乙醇中，将siCCR1置于柠檬酸缓冲液中，乙醇相和水相通过微流体装置混合，在PBS溶液中透析两小时后制备成脂质纳米粒。该脂质纳米粒与聚卡波非、泊洛沙姆复配，制备得到复合水凝胶。该水凝胶可于子宫病灶局部释放siCCR1，有效抑制组织纤维化、减少胶原沉积，进而实现子宫瘢痕修复。其具备优异的生物相容性，给药方式无创，可实现药物长效缓释，减少给药频次。

LIPID NANOPARTICLES FOR INDUCING TOLERANCE IN HUMAN CELLS

Resumen de: WO2026180744A1

The invention provides a lipid composition or LNP comprising (i) one or more cationic ionizable lipids and, optionally, one or more permanent cationic lipids, (ii) one or more phospholipids, (iii) one or more amphiphilic compounds comprising a hydrophilic polymer chain having one or more hydrophobic groups, (iv) optionally cholesterol or a cholesterol ester, (v) a lipophilic agent other than cholesterol and a cholesterol ester, and (vi) one or more polynucleotide(s).

ARIPIPRAZOLE PRODRUG COMPOSITION

Resumen de: US20260256776A1

Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.

NANOPARTICLE POLYMER ENCAPSULATION SYSTEM

Resumen de: US20260256943A1

Generally, a nanomaterial polymer encapsulation system useful in the production of nanocomposites comprising an inorganic nanoparticle encapsulated in a hydrophobic region of a polymer with the external hydrophilic region of the polymer ensuring water-solubility and affording a functional group which can be utilized for the production of nanocomposite conjugates.Specifically, particular embodiments can comprise nanocomposites including one or more inorganic nanoparticles including, metal and non-metal isotopes, a superparamagnetic iron oxide nanoparticle (“SPION”), and/or quantum dots encapsulated in a polystyrene-b-polyethylene glycol affording a functional group that can be activated to conjugate antibodies, modified antibodies, or antibody fragments for the capture of target moieties which in suspension can be nebulized into an inductively coupled plasma time-of-flight mass spectrometry instrument to identify and quantify diverse features of cellular systems.

PH-RESPONSIVE SYNTHETIC PEPTIDE SHUTTLE AGENTS

Resumen de: WO2026178657A1

Described herein are pH-responsive synthetic peptide shuttle agent having increased cargo transduction activity at acidic pH than at neutral pH. The pH-responsive synthetic peptide shuttle agent generally comprises an amphipathic alpha-helical motif when in acidic pH, the amphipathic alpha-helical motif having solvent-exposed surface comprising a discrete hydrophilic cationic face and a discrete hydrophobic face. The pH-responsive synthetic peptide shuttle agent described herein may be further conjugated to a cargo for intracellular delivery, and/or a targeting ligand for tissue-specific delivery. Also described herein are lipid nanoparticles (LNPs) incorporating synthetic peptide shuttle agents or pH- responsive synthetic peptide shuttle agents for improved payload delivery to the cytosol.

BRANCHED CATIONIC LIPID CONTAINING ESTER BOND AND USE THEREOF

Resumen de: WO2026179355A1

The present application provides a branched cationic lipid containing an ester bond, the structure of which is represented by formula (1), wherein the definition of each symbol is consistent with that described herein. The branched cationic lipid containing an ester bond has a plurality of hydrophobic hydrocarbon tail chains. The cross-sectional area of the hydrophobic end increases, forming a conical geometric configuration, which is conducive to promoting membrane fusion and content release; moreover, a charged head group can interact with oppositely charged molecules on the cell membrane, thereby enabling the multi-tailed lipid to pass through the cell membrane more easily and exert its endosome-disrupting effect inside the cell, and thus improving drug release efficiency. The branched cationic lipid containing an ester bond of the present application comprises one or more biodegradable groups between a branching center and the hydrophobic tails. The presence of the degradable groups enables a lipid nanoparticle (LNP) prepared from the branched cationic lipid to be degraded timely within endosomes, such that the endosomal escape of drug molecules (such as nucleic acids) is promoted, thereby solving the problem that drugs delivered into the cell fail to exert their effects.

ACTIVATION OF CELLS WITH SELF-ASSEMBLED SPHERES

Resumen de: WO2026180422A1

The invention is directed to a compound for cell activation having a mean diameter between 500 nm and 10 µm and provided with one or more antigen recognizing moieties capable of activating cells characterized in comprising - first particles with a mean diameter of less than 500 nm which are provided on the surface with one or more first oligonucleotides having a length of 5 to 50 nucleotides - second particles with a mean diameter of less than 500 nm which are provided on the surface with one or more second oligonucleotides having a length of 5 to 50 nucleotides and with one or more antigen recognizing moieties wherein the first and second oligonucleotides have complementary sequences capable of hybridizing to each other, thereby binding the first and second particles to each other.

MULTI-SPECIFIC TARGETING COMPOSITIONS

Resumen de: WO2026183563A2

Compositions and methods for targeted delivery of a lipid nanoparticle (LNP) are described herein. In some embodiments, the compositions comprise (a) a hepatoavoidant lipid nanoparticle (LNP) associated with an RNA polynucleotide that comprises an expression sequence, and (b) a multi-specific targeting moiety, wherein the multi-specific targeting moiety binds (i) at least one target in or on the hepatoavoidant LNP and (ii) at least one cell-specific target in or on a cell. In some embodiments, the compositions comprise a multi-specific targeting moiety or an RNA polynucleotide comprising an expression sequence encoding a multi-specific targeting moiety, where the multi-specific targeting moiety binds (a) at least one target in or on an LNP, and (b) at least one cell-specific target. When expressed, the multi-specific targeting moiety allows for delivery of the LNP to the cells expressing the cell-specific target, by bringing the LNP in close proximity to the cells. In some embodiments, the LNP comprises an expression sequence encoding a therapeutic molecule, and the methods allow for targeted delivery for treating or preventing a disease or disorder.

TARGETED LIPID NANOPARTICLES

Resumen de: WO2026183200A1

The present disclosure provides, among other things, targeted lipid nanoparticles and methods of targeted making lipid nanoparticles.

ORAL NANOPARTICLES FOR BIOACTIVE COMPOUND, AND METHOD OF PREPARING SAME

Resumen de: US20260256708A1

Provided are: oral nanoparticles for enabling oral administration of a bioactive compound which is typically administered by injection due to having low bioavailability attributable to issues with solubility, disintegration in the digestive tract, and intestinal permeability; a method of formulating the oral nanoparticles; and a use of the oral nanoparticles. In addition, provided are: oral nanoparticles capable of maintaining or protecting the balance in the gut microbiome by minimizing the exposure of the gut microbiome to a bioactive compound; a formulation; and a use of same.

NANOCOMPOSITE COMPOSITION

Resumen de: WO2026180833A1

The subject of the invention is a core–shell structured nanocomposite composition comprising a core containing glibenclamide and soybean lecithin having phosphatidylcholine as a main component, and a shell containing a Poloxamer polymer. The invention further relates to the use of the nanocomposite composition in human medicine and/or veterinary medicine.

PEGYLATED LIPID NANOPARTICLES MODIFIED WITH CELL PENETRATING PEPTIDES FOR DELIVERY OF NUCLEIC ACIDS

Resumen de: WO2026183439A1

The present disclosure provides compositions of lipid nanoparticles including lipid components and a cell-penetrating peptide conjugated to the lipid components useful for the delivery of nucleic acids including mRNAs, and methods thereof. These compositions may be used to treat a disease or disorder for which the delivery of a nucleic acid is therapeutically effective.

PIEZOELECTRIC CHITOSAN NANOPARTICLES AND THEIR USE IN BIOMEDICAL APPLICATIONS

Resumen de: WO2026181030A1

It forms an object of the present invention chitosan piezoelectric nanoparticles (ChNPs), methods to prepare them and their use.

pH-RESPONSIVE LIPID DERIVATIVE

Resumen de: WO2026181880A1

The present invention provides a pH-responsive lipid derivative represented by formula (1): R1-L1-R2 (in the formula, R1 represents a lipid moiety, L1 represents NH or O, and R2 represents a polymer moiety having a repeating unit represented by formula (2) and a repeating unit represented by formula (3)), wherein the amount of a repeating unit (B) based on the total amount of a repeating unit (A) and the repeating unit (B) is 6 to 50 mol% (the symbols in formulae (2) and (3) are as defined in the description).

ORAL GENE DELIVERY CARRIER

Resumen de: WO2026182546A1

The present invention relates to an oral gene delivery carrier and a gene delivery composition comprising same. The present invention comprises lipid nanoparticles surface-modified with a bile acid-based polymer (GCGA), and provides improved stability in the gastrointestinal (GI) environment, enhanced mucosal adhesion and cellular uptake, and significantly increased gene delivery efficiency in intestinal epithelial cells, thereby being useful for the development of an oral gene therapeutic agent.

IONIZABLE LIPID MOLECULE COMPRISING TOCOPHEROL STRUCTURE, LIPID NANOPARTICLE COMPRISING SAME, AND USE THEREOF

Resumen de: WO2026178739A1

The present invention relates to an ionizable lipid molecule comprising a tocopherol structure, a lipid nanoparticle comprising same, and use thereof. Specifically, provided are an ionizable lipid molecule comprising a structure of a tocopherol and a derivative thereof as represented by formula (1), a lipid nanoparticle comprising same, a preparation method therefor, and use thereof. Compared with ionizable lipid molecules conventionally used in the art, the lipid nanoparticle prepared from the ionizable lipid molecule represented by formula (1) of the present invention can significantly improve nucleic acid delivery efficiency and expression.

LIPID NANOPARTICLES TARGETING LIVER SINUSOIDAL ENDOTHELIAL CELLS AND USE THEREOF

Resumen de: WO2026179939A1

Lipid nanoparticles (LNPs) targeting liver sinusoidal endothelial cells and the use thereof. The LNPs consist of a cationic ionized lipid, an auxiliary lipid, a ligand-modified PEGylated lipid, and cholesterol. The auxiliary lipid and the ligand-modified PEGylated lipid target surface receptors of the liver sinusoidal endothelial cells (LSECs). The LNPs enhance, by means of a multivalent targeting design, specific uptake by LSECs, and encapsulate an RNA drug for treating an allergic disease or an autoimmune disease. The RNA drug can encode at least one epitope of an antigen causing an allergic or autoimmune disease. The LNPs can efficiently target LSECs to induce immune tolerance, providing a new antigen-specific immunomodulatory strategy for the treatment of allergic diseases or autoimmune diseases.

USE OF IRON NANOPARTICLE IN PREPARATION OF PRODUCT FOR CONTROLLING BABESIA

Resumen de: WO2026179540A1

The present invention belongs to the field of biomedical science, and specifically relates to the use of an iron nanoparticle in the preparation of a product for controlling Babesia. The iron nanoparticle is in the form of a polysaccharide-coated superparamagnetic iron oxide injection or other formulated products containing the main active ingredient thereof. The iron nanoparticle is used for administration to a subject in the presence of a magnetic field. It has been demonstrated by experiments of the present invention that the iron nanoparticle has a good control effect on Babesia with a weak reproductive capacity under the action of an external magnetic field.

ENGINEERED EXOSOMES FOR IMPROVING WOUND HEALING

Resumen de: WO2025152910A1

Disclosed is an engineered exosome, comprising (a) an EGF polypeptide, fused to a first anchoring polypeptide, (b) a NGF polypeptide, fused to a second anchoring polypeptide, and (c) a PDGF-BB polypeptide, fused to a third anchoring polypeptide, wherein (a), (b) and (c) are anchored on a membrane of the exosome via the first, second and third anchoring polypeptide, respectively, and wherein the EGF polypeptide, the NGF polypeptide and the PDGF-BB polypeptide are exposed on an outer surface of the membrane of the exosome. Also disclosed are compositions, nucleic acid constructs, and uses of the exosome for wound healing.

COMPOSITIONS FOR CANCER THERAPEUTICS

Resumen de: WO2025160108A1

This invention describes therapeutic compositions, uses and methods using deciparticles for cancer drug delivery. Deciparticle compositions of this invention can be composed of one or more taxane drug compounds complexed with amphiphilic molecules. The amphiphilic molecules may comprise a polyethylene glycol hydrophilic oligomer and a fatty acid alkanoyl hydrophobic core.

DENDRIMER NANOPARTICLES FOR TREATING KIDNEY DISEASES AND METHODS OF USE THEREOF

Resumen de: WO2026183193A1

Disclosed are nanoparticles and compositions thereof for delivering active agents to the kidney. The nanoparticles include a dendrimer, a targeting ligand, and one or more active agents. From 5% to less than 90% of the dendrimer's surface groups can be modified with one or more functional groups e.g., acetyl groups. The dendrimer can be a PAMAM dendrimer or a saccharide dendrimer. The targeting ligand, such as folic acid, is conjugated to unmodified surface groups. Active agents, including small molecules (e.g., PPAR-α agonists), peptides, or nucleic acids, are encapsulated or associated with the nanoparticles. The nanoparticles have a neutral or positive zeta potential, ranging from about 0 mV to about 30 mV, and a diameter of ranging from 1 to 30 nm. Also disclosed are methods of administering the nanoparticle compositions for treating kidney diseases in a subject in need thereof.

ULTRA-SMALL METALLIC NANOPARTICLES

Resumen de: WO2026181080A1

Metal nanoparticles comprising at least one metal atom and a ligand associated with at least a portion of a surface of the metal atom, and uses thereof, are provided. The ligand is made of a first moiety (denoted as X) that is capable of associating with the surface of the metal atom; and an additional moiety (denoted as Y) which is a redox-reactive moiety and/or a second moiety that is capable of associating with the surface of the metal atoms, and optionally a linking moiety that links the first moiety and the additional moiety. The metal nanoparticles are ultra-small nanoparticles. The metal nanoparticles are usable in, for example, catalyzing redox reactions and as coatings for varying surfaces, and are capable of interacting with a myriad of substances, such as liposomes and oligonucleotides, rendering these nanoparticles usable in varying applications.

NANOPARTICLE IMMUNOSUPPRESSANT FOR RETINAL APPLICATIONS

Resumen de: WO2026183437A1

Provided herein are pharmaceutical compositions that include (a) a dendrimer nanoparticle, wherein the dendrimer nanoparticle comprises Dexamethasone-21-succinate, and (b) a plurality of retinal cells. Also provided herein are methods for treating a degenerative and hereditary retinopathy that include administering any one of the pharmaceutical compositions described herein to a subject in need thereof.

CUPROPTOSIS-DRIVEN NANORADIOTHERAGNOSTICS FOR CANCER

Resumen de: WO2026183342A1

The present technology relates generally to nanoparticles including bovine serum albumin and a first copper complex including diethyldithiocarbamate and Cu2+, and optionally including a second copper complex including diethyldithiocarbamate and 64Cu2+, and optionally including a third copper complex including diethyldithiocarbamate and 67Cu2+ for treating, imaging, and/or detecting a cancer.

CIRCULAR RNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TARGETED DELIVERY

Resumen de: WO2026183142A2

The present disclosure provides compositions, methods of making, and use of a circular ribonucleic acid (circRNA) therapeutic for targeted delivery to immune cells, including T cells, for effector functions such as B cell depletion, providing, among other things, methods of treating B cell-mediated diseases such as autoimmune disease and cancer, meeting the medical need for efficacious and safe therapies that overcome the disadvantages of ex vivo CAR T therapy. Provided by the present disclosure is a circRNA therapeutic comprising: (i) a circRNA comprising a ribosome recruiting element, and a coding sequence encoding a CAR comprising, for example, an anti-CD19 antibody or antigen-binding fragment thereof, and (ii) a targeting moiety (e.g, anti-CD5) that binds to an immune cell (e.g., a T cell), wherein the circRNA is in a delivery vehicle, and a targeting moiety that binds to a T cell is conjugated to the delivery vehicle (e.g, a lipid nanoparticle).

HAFNIUM-BASED COMPLEX PROTEIN NANOPARTICLE FOR RADIOTHERAPY SENSITIZATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026179183A1

A hafnium-based complex protein nanoparticle for radiotherapy sensitization, a preparation method therefor and the use thereof. Hafnium ions in solution are used, which enter a protein cavity and then form a complex (precipitate) with hexametaphosphate ligand ions, i.e., biomineralization occurs (with the preparation being completed at room temperature), thereby obtaining a protein-encapsulated hafnium-based complex nanoparticle. When exposed to X-ray radiation, the nanoparticle can enhance the effect of radiotherapy.

COMPOSITIONS AND METHODS FOR ALTERING COMPLEMENT ACTIVATION

Resumen de: US20260258407A1

0000 Compositions and methods for reducing complement activation by introducing one or more alterations into a complement factor B (CFB) polynucleotide in a cell. In particular embodiments, the invention of the disclosure features a base editor system (e.g., a fusion protein or complex comprising a programmable DNA binding protein, a nucleobase editor, and gRNA) for modifying a CFB polynucleotide, where the modification is associated with reduced expression, and/or reduced activity of the CFB polypeptide encoded by the polynucleotide.

IMMUNO-TARGETING THE ECTOPIC PHOSPHORYLATION SITES OF PDGFRA GENERATED BY MAN2A1-FER FUSION IN HEPATOCELLULAR CARCINOMA

Resumen de: US20260258142A1

0000 The presently disclosed subject matter relates to antibodies and antigen-binding fragments that bind specifically to phosphorylated PDGFRA, and methods of treating cancer expressing MAN2A1-FER which ectopically phosphorylates PDGFRA. MAN2A1-FER can be expressed in liver cancer, prostate cancer, brain cancer, glioblastoma multiforme, breast cancer, lung cancer, non-small cell lung cancer, colon cancer, and renal cell carcinoma.

LIPID FORMULATION USING MULTI-COMPONENT CONDENSATION REACTION AND LIPID NANOPARTICLES MADE USING THE SAME

Resumen de: US20260256707A1

Disclosed herein are aspects of a compound according to Formula IAlso disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and/or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some aspects, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.

逆転写媒介遺伝子編集システムおよびその使用

Resumen de: WO2025049928A1

A gene editing system comprising (a) a fusion polypeptide comprising a CRISPR nuclease and a reverse transcriptase, or a nucleic acid encoding the fusion polypeptide, and (b) an RNA molecule comprising a guide RNA and a reverse transcription donor RNA, or a nucleic acid encoding the RNA molecule. Also provided herein are methods of using the gene editing system for modifying target genes of interest.

BIODEGRADABLE DENDRITIC PARTICLES FOR SUSTAINED DRUG RELEASE

Resumen de: US20260256709A1

0000 Described herein are methods, systems and compositions for the production and use of a class of highly branched, nanostructured particles, generally referred to herein as dendritic particles (DPs), synthesized from biodegradable materials that are specifically adapted for drug release in vivo.

MiRNA FOR CONTROLLING EXPRESSION OF IN VIVO DELIVERY CONSTRUCTS

Resumen de: US20260258413A1

Compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for stable and durable expression are described and can be suitably used for immunotherapy in cancer or infection.

CATALYTIC RNA FOR THE INDUCTION OF PROTEIN EXPRESSION AND/OR CODING A CONSORTIA POPULATION

Resumen de: US20260258411A1

0000 The present disclosure is directed to self-cleaving ribozyme constructs designed to target specific organisms and introduce exogenous sequences—both coding and non-coding-into expressed RNAs of the target host cell.

METHOD FOR FUSING LIPID NANOPARTICLES

Resumen de: US20260258503A1

According to one embodiment of the present disclosure, a method for fusing lipid nanoparticles is provided. In some embodiments, the method is a method including: causing a fibrous structure to capture a first lipid nanoparticle; causing the fibrous structure to capture a second lipid nanoparticle; and causing the fibrous structure to contract.

Combined Therapy with Nanoparticles and Radiopharmaceuticals

Resumen de: US20260256963A1

The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an efficient amount of said high-Z element containing nanoparticles and of an efficient amount of a radionuclide containing therapeutic radiopharmaceutical, wherein the high-Z element containing nanoparticles contain an element with an atomic Z number higher than 40, preferably higher than 50, and wherein said nanoparticles have a mean hydrodynamic diameter of 20 nm or less, for example between 1 and 10 nm, preferably between 2 and 8 nm.

LIPID NANOPARTICLE AND METHOD FOR PRODUCING SAME, NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLE AND METHOD FOR PRODUCING SAME, AND METHOD FOR INDUCING ACQUIRED IMMUNITY IN LIVING BODY BY USING NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLE

Resumen de: US20260256696A1

0000 The present invention provides lipid nanoparticles containing (A) an ionic lipid represented by the formula (1): 0000 0000 (the symbols in the formula (1) are as defined in the DESCRIPTION), (B) vitamin E and/or a derivative thereof, (C) phospholipid, (D) cholesterol, and (E) PEG lipid.

LIPID NANOPARTICLE FORMULATIONS FOR VACCINES

Resumen de: US20260256705A1

0000 Provided is a lipid formulation capable of forming a lipid-based nanoparticle comprising an ionizable lipid to phospholipid molar ratio of 0.1-1.30 of in association with a nucleic acid payload, and in some embodiments, a stabilizing agent. In embodiments, the nucleic acid payload is a vaccine genetic element.

MITOCHONDRIA AS A TARGETED DELIVERY PLATFORM

Resumen de: US20260256940A1

0000 The current invention focuses on ways to deliver various payloads including nucleic acids molecules (such as oligonucleotides), polypeptides (such as proteins), drugs or a combination thereof. As such, the invention relates to, inter alia, a mitochondrion comprising one or more payload(s) attached to the outer membrane of the mitochondrion, wherein the payload(s) is indirectly or directly electrostatically attached to the outer membrane of the mitochondrion. The invention further involves combining mitochondria comprising one or more payload(s) attached to the outer membrane of the mitochondrion with a protective layer that envelopes/encapsules and/or coats the mitochondrion and payload to provide a further delivery platform. This methodology is particularly effective for increasing the uptake and efficiency of the one or more payload(s) for therapeutic purposes.

AMINO ACID-BASED CATIONIC LIPID

Resumen de: US20260257986A1

0000 The present invention introduces a novel amino acid-based cationic lipid, represented by the general formula (1), with symbols as defined herein. This lipid is pharmaceutically acceptable, biodegradable, or highly biocompatible, and offers low toxicity, low immunogenicity, and high compatibility. The amino acid or its derivatives used as starting materials are easily accessible, either naturally or through simple synthesis, making the process straightforward, safe, and cost-effective. The lipid structure may include degradable groups between the amino acid residue and lipophilic tail chains. The presence of degradable groups allows lipid nanoparticles (LNPs) to degrade within endosomes, addressing issues of LNP accumulation and endosomal acidification caused by non-degradable lipids in prior art. This facilitates the effective endosomal escape of drug molecules, such as nucleic acids, ensuring their proper cellular function after delivery. 0000

SURFACE-MODIFIED NANODIAMOND

Resumen de: US20260256917A1

To provide a surface-modified nanodiamond that enables selective accumulation of a sufficient amount of boron atoms in a cancer tissue or a cancer cell and has high killing and injuring ability against the cancer cell. The surface-modified nanodiamond of the present disclosure contains a nanodiamond particle, and a boron cluster-containing group and a group capable of recognizing a cancer cell as surface modification groups of the nanodiamond particle.

PROCESS FOR SYNTHESIZING POLY(SPERMINE ACRYLAMIDE) AND/OR POLY(SPERMINE ACRYLAMIDE-CO-N-ALKYLACRYLAMIDE) AND THEIR APPLICATION

Resumen de: US20260258177A1

The present invention relates to a process for the synthesis of poly(spermine acrylamide) and/or poly(spermine acrylamide-co-N-alkylacrylamide), the process comprising the following steps: a) reacting a mixture of N-acryloxysuccinimide with N-alkylacrylamide, and b) obtaining poly(N-acryloxysuccinimde) polymers, poly(N-alkylacrylamide) polymers and/or copolymers with varying ratios of N-acryloxysuccinimide and N-alkylacrylamide, and c) treating the obtained polymers and/or copolymers of step b) with at least 0.1 equivalent of tri-boc spermine per N-acryloxysuccinimide-repeating unit and obtaining poly(spermine acrylamide) and/or poly(spermine acrylamide-co-N-alkylacrylamide) polymers.

STEALTH-STABILIZED LIPO-POLYAMINO ACIDS

Resumen de: US20260256704A1

0000 It relates to lipo-polyamino acid conjugates of formula (I), and acceptable salts, stereoisomers and mixtures thereof. It also relates to self-assembled particles comprising these lipo-polyamino acid conjugates and optionally active agents, and to compositions comprising the lipo-polyamino acid conjugates or the self-assembled particles comprising them. It relates as well to the use of the lipo-polyamino acid conjugates, self-assembled particles, or compositions comprising them in medicine, cosmetics and diagnostics, and to the use of the lipo-polyamino acid conjugates of formula (I) as carriers. 0000

Ionizable Lipid Compounds and Lipid Nanoparticle Compositions

Resumen de: US20260258002A1

0000 Novel ionizable lipids, compositions, and methods of using the novel ionizable lipids and compositions are disclosed. Lipid nanoparticle compositions include a novel ionizable lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticle compositions further including biologically active agents such as mRNA or DNA are useful in the delivery of biologically active agents to mammalian cells or organs.

REHYDRATABLE, MORPHOLOGICALLY DIVERSE NANOCARRIER POWDERS

Resumen de: US20260256698A1

Provided herein are rehydratable powdered formulations of nanocarriers that can be used to encompass hydrophobic or hydrophilic cargo. The formulations can be used for medicinal, agricultural, and research applications. Methods of making the formulations are also provided.

LIPID NANOPARTICLE

Resumen de: US20260256706A1

The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a linear or branched C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B)(d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group. (I) (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X. (A): (R11)(R12)—CH—(CO—O)c-(CH2)v-. (B):—(CH2)d-N(R3)(R4).

CERIUM OXIDE NANOPARTICLE, DISPERSION SOLUTION CONTAINING CERIUM OXIDE NANOPARTICLE, OXIDANT, ANTIVIRUS AGENT, AND ANTIBACTERIAL AGENT

Resumen de: US20260256146A1

0000 A cerium oxide nanoparticle is produced by adding an oxidant to a solution comprising a boron compound represented by formula (I) and a cerium (III) ion: 0000 wherein n represents an integer of 0 to 2, R represents any of an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and R′ represents any of a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and when a plurality of Rs or of R's are present, the plurality of Rs or of R's are optionally the same or different.

標的ＲＮＡ送達のための組成物および方法

Resumen de: CN115484932A

Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents to alter the expression and function of target genes, such as proteins involved in lipid and cholesterol metabolism, such as PCSK9. Also provided herein are compositions and methods for treating conditions associated with coronary artery disease.

COMPOSITIONS AND METHODS FOR IN UTERO DELIVERY

Resumen de: US20260256690A1

Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregnant mother. Fibroblast growth factor is to correct structural defects of neural tissue.

Glypican 2 as a cancer marker and therapeutic target

Resumen de: AU2026216842A1

The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen. ug u g

Nanocarrier Composition with Adjustable Structure, Preparation Method and Use Thereof

Resumen de: US20260256942A1

The present disclosure discloses a nanocarrier composition with adjustable structure, preparation method and use thereof. The nanocarrier composition is prepared by adding a regulator to lecithin. By adding different types of regulators, the nanocarrier composition can be converted between a liposome structure or a micelle structure. When applied to medical purposes, under the same nanocarrier composition preparation process, under the same nanocarrier composition manufacturing process, the structure of the nanocarrier composition can be changed by simply changing the type of added regulator, thereby controlling the drug release time, drug penetration and bioavailability. The nanocarrier composition can be converted into a suitable structure to facilitate drug delivery according to the requirements of different dosage forms.

ENCAPSULATED COMPOSITIONS FOR DENTAL AND BONE REMINERALISATION

Resumen de: EP4799601A1

0001 The present invention relates to the field of medicinal tissue mineralisation, in particular, i.e. tooth remineralisation and bone regeneration with self-assembling peptides. Use of self-assembling peptides, such as P11-4, also designated Oligopeptide-104, in these processes leads to generation of hydroxyapatite, which is also present in natural enamel, dentin and bone. The inventors have discovered that this can be significantly accelerated by combining a self-assembling peptide (SAP) such as P11-4, calcium ions, phosphate ions, and a polymer in the form of particles encapsulating a cargo selected from at least one of the SAP, the calcium ions and the phosphate ions into a composition or kit. The invention also provides medical use of said composition or kit, in particular, in the tooth, for remineralisation of caries lesions, such as subsurface caries lesions, mineralisation of pits and fissures, treatment of sensitive teeth, pulp capping, and for bone regeneration.

IMMUNOLOGIC ADJUVANT COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: EP4799638A1

Provided are an immunological adjuvant composition, a preparation method and use thereof. The immunological adjuvant composition comprises an immune activator and a liposome for loading the immune activator, wherein the immune activator includes a saponin and a CpG oligodeoxynucleotide. The immunological adjuvant composition is capable of eliciting an immune response against human herpesvirus and/or hepatitis B virus in a mammal and inducing a strong level of cellular immune response. By using the liposome to simultaneously load QS21 and the CpG oligodeoxynucleotide, the two components exhibit a favorable synergistic effect in promoting cellular immunity, and can induce a stronger level of cellular immune response compared to the commercially available vaccine Shingrix.

ALGA(E) NANOPARTICLES AND USES THEREOF FOR DRUG DELIVERY

Resumen de: WO2025088609A1

Disclosed are biocompatible, biodegradable, and low immunogenic alga(e) Nanoparticles (aNPs) that can adhere and deliver active ingredient(s) to mucosal epithelium tissue, as well as compositions comprising the aNPs, methods of preparing the aNPs, and uses thereof in methods of treatment.

NANOPARTICLE BASED DELIVERY OF MITOCHONDRIAL DNA (MTDNA) AND METHODS OF USE THEREOF

Resumen de: WO2025090891A1

In some embodiments, the invention relates to a composition for targeted delivery of intact mitochondrial DNA (mtDNA) to a target cell, the composition comprising a mtDNA molecule that is complexed to cell-penetrating peptides (CPPs) which promote cellular entry, wherein the complex forms a nanoparticle with the CPPs bound to the mtDNA molecule. In some embodiments, the invention relates to a method of treating a disease or disorder associated with mitochondrial dysfunction in a subject in need thereof.

BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: WO2025090417A1

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: WO2025090138A1

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, hematopoietic stem cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

NANOPARTICLE COMPOSITION FOR DRUG DELIVERY

Resumen de: EP4799614A1

0001 The present invention relates to a composition for drug delivery and a preparation method therefor and, more specifically, to: a composition for drug delivery which is formed such that a drug is encapsulated inside a nanoparticle structure formed by a polymer and a cationic lipid having a specific structure; and a preparation method therefor.

NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME

Resumen de: WO2025090663A1

The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.

COMPOSITIONS AND METHODS FOR TARGETING LIPID NANOPARTICLES

Resumen de: WO2025085950A1

The present invention is directed to lipid-based nanoparticles (e.g. lipid nanoparticles), formulations containing lipid-based nanoparticles and methods of treating diseases or conditions with said lipid-based nanoparticles and formulations thereof. The present invention provides a lipid-based nanoparticle comprising (a) an active agent, and (b) a plurality of capture binding domains displayed on the outer surface of the nanoparticle, wherein each capture binding domain is linked to the lipid-based nanoparticle through a site-specific linkage such that each capture binding domain is displayed in substantially the same orientation and capable of capturing a targeting moiety in an orientation that allows the targeting moiety to interact with its target. The present invention also provides a lipid-based nanoparticle comprising (a) an active agent, and (b) a plurality of targeting molecules displayed on the outer surface of the nanoparticle, wherein each targeting molecule is linked to the lipid-based nanoparticle through a site-specific linkage such that each targeting molecule is displayed in substantially the same orientation and capable of binding to a target on a cell surface.

IONIZABLE LIPIDS AND USES THEREOF

Resumen de: WO2025089791A1

The present invention relates to a novel ionizable lipid compound represented by Formula (I) or a salt thereof, and a lipid nanoparticle containing the same. The lipid nanoparticle containing the novel ionizable lipid compound according to the present invention has an excellent nucleic acid encapsulation efficiency and has a high efficiency of cellular delivery of nucleic acid.

IONIZABLE LIPID AND USE THEREOF

Resumen de: EP4800017A1

0001 The present invention relates to a novel ionizable lipid compound represented by Formula (I), or a salt thereof, and lipid nanoparticles comprising same. The lipid nanoparticles comprising the novel ionizable lipid compound, according to the present invention, have excellent nucleic acid encapsulation efficiency and high nucleic acid cell delivery efficiency.

METHODS FOR THE COUPLING OF DI(ALKYL)AMINES TO POLYPEPTIDES

Resumen de: WO2025088192A1

The present invention provides for inventive means and methods for the coupling of di(alkyl)amines to polypeptides or peptides capable of forming a random coil conformation. The present invention further provides inventive compounds produced by the herein detailed methods, wherein said compounds are characterized by formula (I): A-B-bC-D. Said compounds comprise a polypeptide/peptide capable of forming a random coil conformation, an N-terminal protecting group, a di(alkyl)amino group, and optionally a linker. Furthermore, the present invention provides lipid nanoparticles comprising said compounds characterized by formula (I) as well as means and methods for the production of said lipid nanoparticles. Formulations comprising the inventive compounds and/or the lipid nanoparticles of the present invention are also provided. Further, the present invention also relates to uses of the inventive compounds, the lipid nanoparticles, and/or the formulations disclosed herein.

ABCB5-TARGETED STEM CELL REPROGRAMMING AND ANTI-AGING STRATEGIES

Resumen de: WO2025090565A1

Methods and compositions for rejuvenating and reprogramming stem cells are disclosed. The methods involve administering to a subject an ABCB5 targeted composition comprising an anti-ABCB5 antibody conjugated to a therapeutic payload comprised of an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor in an effective amount to reprogram and rejuvenate ABCB5+ stem cells in the subject. The compositions include anti-ABCB5 antibody conjugated to a therapeutic payload comprising an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor.

分岐頭基を有するイオン化可能な脂質

Resumen de: US20260176252A1

0000 The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use such as a compound of Formula (A) or a pharmaceutically acceptable salt thereof. 0000

COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Resumen de: EP4799694A2

The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.

一种包载THL的靶向巨噬细胞脂质纳米颗粒及其制备方法与应用

Resumen de: CN122664957A

本发明涉及生物医药、纳米药物递送及免疫调控技术领域，特别是涉及一种包载THL的靶向巨噬细胞脂质纳米颗粒及其制备方法与应用。将二甲氨丁酸二亚油甲酯、胆固醇、培化磷脂酰乙醇胺、磷脂酰丝氨酸和有机溶剂混合，将得到的混合液旋转蒸发成膜，得到脂质膜；将脂质膜水化，得到脂质体混悬液；将脂质体混悬液与焦碳酸二乙酯处理水混合、过滤，滤液为过滤脂质体混悬液；将过滤脂质体混悬液与Thiolutin溶液混合，离心得到的沉淀为包载THL的靶向巨噬细胞脂质纳米颗粒。本发明通过提高THL的巨噬细胞靶向富集能力及生物利用度，实现对因巨噬细胞BRISC过度激活导致的急性及慢性炎症性疾病的调控。

脂质纳米颗粒及工程化改造的免疫细胞

Resumen de: CN121910694A

The invention belongs to the technical field of biological medicine, and particularly relates to lipid nanoparticles, a preparation method thereof and application of the lipid nanoparticles in immune cell delivery. According to the invention, amino acid derived lipid is introduced as a fifth component on the basis of a preferable four-component formula. Through screening of the nitrogen-phosphorus ratio, the introduction proportion of the amino acid-derived lipid and the type of the amino acid-derived lipid, the novel lipid nanoparticles capable of efficiently delivering the primary immune cells are preferably selected. According to the delivery carrier, the delivery efficiency of primary immune cells, especially NK cells, can be remarkably improved, and a safe and efficient tool is provided for clinical application of immune cell engineering and immune cell treatment.

ＣＤ７０を遺伝子改変するための組成物及び方法

Resumen de: WO2025038642A1

Compositions and methods for editing, e.g., altering a DNA sequence, within a CD70 gene are provided. Compositions and methods for reducing or eliminating CD70 protein expression in a cell are provided. Compositions and methods for immunotherapy are provided.

非全身性ｍＲＮＡ投与

Resumen de: WO2025036956A1

The present invention relates to compositions designed for localized delivery within a subject's body. More particularly, the invention pertains to therapeutic compositions that remain localized to specific organs or tissues and do not exhibit systemic distribution. These compositions include specific carriers and therapeutic agents suitable for various medical applications.

薬物送達材料およびその使用

Resumen de: WO2025036455A1

The present invention relates to a drug delivery material and an application thereof. Specifically provided is a nanoparticle composition comprising a lipid component, the lipid component comprising a compound represented by formula (I). The nanoparticle composition of the present invention is delivered only at the site of administration.

ＧＬＰ－１受容体作動薬の局所投与

Resumen de: US20250064897A1

A method of treating type-2 diabetes, chronic weight maintenance, or overindulgence conditions includes administering a pharmaceutically effective amount of a topical composition comprising a GLP-1 receptor agonist suspended in an anhydrous suspension base vehicle to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to form a self-emulsifying liposome in an aqueous environment of the oral cavity.

基于谷氨酸的脂质、包含基于谷氨酸的脂质的脂质纳米颗粒及其制剂

Resumen de: WO2025076625A1

Provided is a glutamic or glutaric acid-based ionizable lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 20 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 10 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. In some embodiments, the ionizable lipid compound is a glutamic acid-based ionizable lipid compound.

一种铂修饰的钒酸铋纳米材料及其制备方法和应用

Resumen de: CN122664956A

本发明公开了一种铂修饰的钒酸铋纳米材料及其制备方法和应用。纳米材料包括钒酸铋（BiVO4）纳米颗粒、沉积在钒酸铋表面的铂（Pt）纳米颗粒以及包覆在最外层的表面功能化系统。本发明纳米材料不仅能通过光动力疗法直接诱导肿瘤细胞凋亡，还能触发免疫原性细胞死亡，释放损伤相关分子模式，从而促进树突状细胞成熟并激活全身性抗肿瘤T细胞免疫反应。本发明为解决肿瘤缺氧及免疫激活不足提供了新的治疗策略。

一种具有抗肠炎活性的sRNA分子及其应用

Resumen de: CN122668972A

本发明公开了一种具有抗肠炎活性的sRNA分子及其应用。该sRNA分子的核苷酸序列如SEQ ID NO.1所示，源自肠道外致病性大肠杆菌的膜囊泡，通过上调BCL2表达、抑制MYD88/NF‑κB信号通路，发挥抑炎抑凋亡双重功能。负载该sRNA的口服结肠靶向纳米递送系统以介孔二氧化硅纳米颗粒为核心，依次经氨基化修饰负载sRNA，并进行透明质酸靶向修饰、聚乙二醇包裹及Eudragit S100肠溶包衣包裹。实验证实，该纳米递送系统能够显著改善结肠炎模型动物的临床症状和病理损伤，具有良好的生物相容性和治疗效果，可用于制备治疗炎症性肠病的药物。

一种带负电的青蒿素脂质纳米颗粒及其制备方法与应用

Resumen de: CN122664959A

本发明属于青蒿素应用技术领域，具体涉及一种带负电的青蒿素脂质纳米颗粒及其制备方法与应用。所述带负电的青蒿素脂质纳米颗粒，由青蒿素类药物、蛋黄卵磷脂和胆固醇按质量比5~15：60~80：5~25通过自组装得到。其中，所述青蒿素类药物为青蒿素、双氢青蒿素、青蒿琥酯、蒿甲醚或蒿乙醚中的任一种。所述青蒿素脂质纳米颗粒由位于外部的亲水结构与位于内部的疏水结构组成。所述蛋黄卵磷脂提供亲水结构，青蒿素类药物和胆固醇的混合物提供疏水结构。所述青蒿素脂质纳米颗粒的粒径为30nm~60nm，zeta电位为‑40mV~‑48mV。本发明的青蒿素脂质纳米颗粒可广泛应用于脱发疾病的治疗，尤其适用于雄激素性脱发，也可用于斑秃、产后脱发等其他类型的脱发。

一种仿生载肽脂质体及其制备方法和应用

Resumen de: CN122668206A

本发明公开了一种仿生载肽脂质体及其制备方法和应用，属于生物医药技术领域。针对耗散自组装体在体内治疗时无法实现针对靶细胞作用的技术问题，本发明设计了具有耗散自组装功能的两亲性六肽nRIMSeIMSeE（nPMSe），在此基础上，进一步构建具有巨噬细胞靶向功能的仿生载nPMSe脂质体（nPMSe@LM）。仿生载肽脂质体nPMSe@LM可将nPMSe特异性递送至巨噬细胞内，通过耗散自组装以持续消除ROS，同时调节巨噬细胞表型并降低促炎细胞因子表达，解决了耗散自组装体在体内治疗时无法实现针对靶细胞作用的关键问题，实现对类风湿关节炎炎症缓解和关节组织修复的同步治疗。

一种靶向三阴性乳腺癌的核壳结构仿生纳米药物及其制备方法和应用

Resumen de: CN122664958A

本发明属于生物医药，具体涉一种靶向三阴性乳腺癌的核壳结构仿生纳米药物及其应用；本发明构建了一种核壳结构的仿生纳米药物递送系统AMT NPs，其以DNA四面体为内核、RAET杂化膜为外壳。该核壳结构平台通过RAET涂层与DNA四面体内核的协同整合，在激活抗肿瘤免疫应答的同时克服耐药性，并降低了载体自身的生物毒性，从而同时解决三阴性乳腺癌治疗中免疫原性缺失、免疫抑制微环境及多药耐药三大关键挑战，为精准癌症免疫治疗提供了新策略。

一种水溶性丝素蛋白富勒烯复合物及其制备方法和应用

Resumen de: CN122664868A

本发明涉及一种水溶性丝素蛋白富勒烯复合物及其制备方法和应用，属于富勒烯改性技术领域，用于解决现有的富勒烯改性方法多采用化学表面活性剂，生物安全性差；改性富勒烯的增殖作用弱、高温稳定性差的问题。包括以下步骤：将富勒烯、丝素蛋白和弱碱性助剂混合，进行球磨，得到第一混合粉体；向第一混合粉体中加入过氧化氢溶液，继续球磨，得到第二混合物料；向第二混合物料中加入水，经超声微流体均质机处理，得到悬浊液；将悬浊液离心，收集上层清液；将上层清液进行透析纯化，得到水溶性丝素蛋白富勒烯复合物水溶液。本发明的水溶性丝素蛋白富勒烯复合物水溶性好，有良好的生物安全性和抗氧化性，有良好的增殖作用和稳定性。

一种纳米颗粒和包含纳米颗粒的囊泡递送系统及其制备方法和应用

Resumen de: CN122664962A

本发明属于生物医药技术领域，公开了一种纳米颗粒和包含纳米颗粒的囊泡递送系统及其制备方法和应用。所述纳米颗粒包括核心及包覆于核心表面的壳层；核心包括具有抗氧化活性的纳米酶，壳层包括多肽。所述囊泡递送系统包括细胞外囊泡和封装于所述细胞外囊泡内部的所述纳米颗粒。可选地，纳米颗粒还可包括包覆于壳层表面的多糖外壳层。本发明提供的纳米颗粒及囊泡递送系统能高效清除活性氧、恢复线粒体功能、逆转髓核细胞应激性衰老，并经体内外实验验证具有显著的抗炎、抗氧化、抗衰老及修复椎间盘结构的效果。

一种纳米颗粒及其制备方法和应用

Resumen de: CN122664963A

本发明属于医药技术领域，尤其涉及一种纳米颗粒及其制备方法和应用。本发明纳米颗粒的制备方法，包括以下步骤：称取COOH‑PEG‑PLGA、NHS、EDC和N,N‑二异丙基乙胺加入DMF中，活化COOH‑PEG‑PLGA，然后加入缀合物进行反应，得到改性PEG‑PLGA；将改性PEG‑PLGA、金丝桃苷和茵芋碱加入丙酮中，配制成油相溶液；将聚乙烯醇加入蒸馏水中，配制成水相溶液；将油相溶液加入水相溶液中，乳化得纳米颗粒。该纳米颗粒以改性PEG‑PLGA为载体，有效提高了金丝桃苷的包载率和心肌细胞靶向性。金丝桃苷与茵芋碱二者联用能够减少心肌缺血区域面积，降低心肌纤维化程度，并改善心功能。

一种超声调控外泌体纳米药物递送系统及其制备方法和应用

Resumen de: CN122664960A

本发明公开了一种超声调控外泌体纳米药物递送系统及其制备方法和应用，属于生物医药技术领域。该纳米药物递送系统包括载体、声敏剂和小干扰RNA，载体为肿瘤细胞经超声调控后分泌获得的超声调控外泌体（US‑Exo），声敏剂和小干扰RNA共同装载在US‑Exo上；制备方法包括对肿瘤细胞进行超声调控，收集细胞培养上清，分离和纯化，获得US‑Exo作为载体，小干扰RNA和声敏剂共同装载在US‑Exo上。本发明的纳米药物递送系统在超声辐照下能精准释放核酸药物和释放ROS杀伤肿瘤细胞，实现声动力治疗与基因沉默治疗的协同作用，可用于制备治疗结直肠癌肝转移的药物，具有重要的应用价值。

一种靶向嗜酸性粒细胞的工程化外泌体制备方法

Resumen de: CN122669028A

本发明涉及生物医药递送技术领域，具体公开了一种靶向嗜酸性粒细胞的工程化外泌体制备方法及其制得的工程化外泌体。所述方法包括：提供外泌体供体细胞；构建包括 Siglec‑8 识别结构域、糖基化保护间隔臂和外泌体膜定位结构域的第一靶向模块；构建包括 CCR3 识别结构域和/或 IL‑5Rα 识别结构域的第二靶向模块；将编码第一靶向模块的核酸构建体导入供体细胞，并将第二靶向模块通过遗传工程方式或外泌体表面后修饰方式引入；培养供体细胞并收集培养上清；分离纯化外泌体；对外泌体进行 Siglec‑8 糖配体密度调控，获得靶向嗜酸性粒细胞的工程化外泌体。该工程化外泌体表面同时具有 Siglec‑8 识别能力以及 CCR3 和/或 IL‑5Rα 识别能力，可提高对嗜酸性粒细胞的靶向结合和递送选择性。

FZD1主动靶向纳米粒的制备方法

Resumen de: CN121868253A

The invention relates to a preparation method of an FZD1 active targeting nanoparticle. The preparation method comprises the following steps: S1, synthesizing DSPE-PEG2000-UM206 by using DSPE-PEG2000-COOH and a polypeptide UM206; and S2, synthesizing the FZD1 active targeting nanoparticles by using the polylactic acid-glycolic acid copolymer and the DSPE-PEG2000-UM206 (Distearoyl Phosphate Polyethylene Glycol 2000-UM206). Due to the adoption of the technical scheme, the FZD1 active targeting nanoparticles prepared by the preparation method of the FZD1 active targeting nanoparticles can promote the phagocytosis of osteosarcoma cells to the PLGA nanoparticles; the phagocytosis efficiency of osteosarcoma dry-like cells (OCSCs for short in subsequent description) on the FZD1 active targeting nanoparticles prepared by the preparation method of the FZD1 active targeting nanoparticles is high.

POLYMERIC SYSTEM WITH NANO-IN-MICRO ARCHITECTURE FOR CONTROLLED RELEASE OF LOW MOLECULAR WEIGHT WATER SOLUBLE DRUGS AND METHOD FOR ITS PREPARATION

Resumen de: BG114050A

The present invention relates to a polymer system with a nano-in-micro architecture (fucoidan micromatrix with PLGA nanoparticles incorporated therein) and finds application as a system for controlled delivery of low molecular weight water-soluble medicinal substances (e.g. galantamine hydrobromide, benzydamine hydrochloride, betahistine hydrochloride, etc.). The system includes polylactic-co-glycolic acid (PLGA) nanoparticles in a fucoidan matrix, with the PLGA content being from 1% to 10% and fucoidan content being from 90% to 99% in the form of a fucoidan matrix with 100% PLGA nanoparticles incorporated therein, with the microparticles having an average diameter of 2 µm to 10 µm. The polymer system for controlled release of low molecular weight water-soluble drugs, when loaded with low molecular weight water-soluble drugs such as galantamine, benzydamine, doxylamine, contains polylactic-co-glycolic acid from 1% to 10% and fucoidan from 90% to 99% in the form of a fucoidan matrix with PLGA nanoparticles incorporated therein, in the form of a fucoidan matrix with PLGA nanoparticles incorporated therein from 94% to 99% and a low molecular weight water-soluble drug from 1% to 6%, wherein the microparticles have an average diameter of 2 µm to 10 µm.

ヒンジドメインを有するヒト化ＮＯＴＣＨ受容体

Resumen de: WO2021207526A1

The present disclosure generally relates to, inter alia, a new class of chimeric Notch receptors containing a fully humanized transcriptional effector, engineered to modulate gene expression and cellular activities in a ligand-dependent manner. The new chimeric Notch receptors surprisingly retain the ability to transduce signals in response to ligand binding despite that the Notch extracellular subunit (NEC), which includes the negative regulatory region (NRR) previously believed to be essential for the functioning of Notch receptors is completely absent. In addition, the new receptors described herein incorporate an extracellular oligomerization domain to promote oligomer formation of the chimeric receptors. Also provided are compositions and methods useful for producing such receptors, nucleic acids encoding same, engineered cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various diseases such as cancers.

一种基于枸杞来源细胞外囊泡的双靶向性仿生纳米颗粒用于早发性卵巢功能不全治疗的方法

Resumen de: CN122643263A

本申请公开了一种基于枸杞来源细胞外囊泡的双靶向性仿生纳米颗粒用于早发性卵巢功能不全治疗的方法，涉及早发性卵巢功能不全技术领域，获取枸杞来源细胞外囊泡，以枸杞来源细胞外囊泡作为纳米递送载体，利用枸杞来源细胞外囊泡携带的活性成分实现对化疗诱导早发性卵巢功能不全相关损伤的治疗作用；采用同源卵巢颗粒细胞膜对枸杞来源细胞外囊泡进行包覆处理，构建具有颗粒细胞识别能力的GCM‑LBEVs仿生纳米囊泡。本申请通过构建TPP‑GCM‑LBEVs双靶向仿生纳米体系，实现卵巢颗粒细胞及线粒体精准递送，改善卵母细胞质量、卵巢功能及生育能力，为POI及线粒体相关生殖障碍治疗提供新型纳米策略。

一种负载CDNF/Rg3仿生脂质纳米颗粒的制备方法和应用

Resumen de: CN122643260A

本发明属于纳米药物递送技术领域，具体涉及一种负载CDNF/Rg3仿生脂质纳米颗粒的制备方法和应用。所述方法通过构建过表达ARC的神经干细胞并提取其细胞膜，采用微流控技术制备负载CDNF circRNA和人参皂苷Rg3的ROS响应性脂质纳米颗粒，再经薄膜挤出获得ARC‑RCD‑LNP。该纳米颗粒经鼻腔给药后可进入脑内，借助ARC相关神经元靶向特性提高受损神经元摄取，并在ROS微环境下释放Rg3和CDNF circRNA；CDNF circRNA翻译为CDNF蛋白，抑制α‑Syn聚集，并与Rg3协同发挥抗炎、抗氧化、缓解内质网应激和抗凋亡作用，从而修复受损神经元并改善运动功能障碍。

一种小反刍兽疫RNA疫苗及其制备方法与应用

Resumen de: CN120550105A

The invention discloses a DNA vaccine, and the DNA vaccine prepared by taking an H gene and an F gene of a peste des petits ruminants virus strain with a microbial preservation number of CCTCC NO: V202487 as coding genes of immunogens has good immunogenicity and immune protection capability, and has an application prospect.

ナノ・イン・マイクロカプセル化治療用核酸乾燥粉末および当該乾燥粉末を含有する医薬品

Resumen de: EP4497433A1

The invention relates to Nano-in-micro (NIM) encapsulated bioactive siRNA dry powder comprising lipid nanoparticles, the lipid nanoparticles comprising from at least an ionizable cationic lipid, a helper lipid, a stealth lipid, and siRNA, wherein the lipid nanoparticles are encapsulated in sugar and/or sugar alcohol, wherein the mass ratio of siRNA to a sugar and/or sugar alcohol is more than 0.10%, especially between 0,90% and 1,30%. The invention also relates to a respective pharmaceutical product containing the dry powder in a sealed volume.

ビエッティ結晶性ジストロフィーの治療用医薬製剤

Resumen de: WO2025030426A1

Provided is a pharmaceutical preparation for treating Bietti's crystalline dystrophy (BCD), comprising a recombinant AAV expressing CYP4V2, sodium chloride, poloxamer, phosphate, and water for injection, and having a pH between 7.0 to 7.6. The pharmaceutical preparation has an excellent virus titer stability, very few AAV aggregates, a high mRNA expression of the target gene after multiple times of freezing and thawing, and/or an excellent high temperature stability. Moreover, the animal experiments in vivo demonstrate that the preparations with the formulations have an excellent property in reducing local inflammatory response of the retina, and further clinical trials demonstrate that the pharmaceutical preparations conform to the relevant technical specifications for safety and effectiveness in the Chinese Pharmacopoeia and the United States Pharmacopoeia (USP).

一种具有液晶性能的嵌段共聚物纳米粒子及其制备方法和应用

Resumen de: CN122647680A

本发明公开了一种具有液晶性能的嵌段共聚物纳米粒子及其制备方法和应用。所述嵌段共聚物纳米粒子结构式如(1)式所示。本发明通过使用聚合诱导自组装方法中动力学陷阱的特点，获得高固含量且尺寸均一的液晶嵌段共聚物纳米粒子。本发明不仅可获得传统蠕虫状液晶嵌段共聚物胶束，并可获得可调节双折射程度的球形液晶嵌段共聚物胶束。本发明不仅提高了液晶嵌段共聚物纳米粒子的可加工性能，亦通过固含量提供显著提升其大规模制造的可能，在高分子材料和生物医药方面有显著的应用价值。

一种选择性包埋人参皂苷Rd的玉米蛋白粒子制备方法及应用

Resumen de: CN122643261A

本发明涉及活性物质包埋递送技术领域，具体涉及一种选择性包埋人参皂苷Rd的玉米蛋白粒子制备方法及应用。制备方法包括以下步骤：（1）将玉米醇溶蛋白溶解于乙醇溶液中；（2）向玉米醇溶蛋白溶液中加入人参总皂苷；（3）配制酪蛋白缓冲液，将酪蛋白缓冲液快速加入上述混合液；（4）采用旋转蒸发方式去除乙醇；（5）过滤纳米粒子分散液；（6）冷冻干燥。现有技术需使用高纯度人参皂苷Rd单体作为包埋原料，粗提物直接包埋又无选择性，产物成分混杂、质量不可控。本发明利用玉米醇溶蛋白对人参皂苷Rd的特异性结合能力，从含多种皂苷混合物中选择性富集人参皂苷Rd，包埋总皂苷中Rd占比可达90%以上。显著降低整体制备成本，适配规模化工业化生产。

RNA及包含其的四价流感疫苗

Resumen de: CN122643425A

本发明公开了RNA及包含其的四价流感疫苗。具体地公开了免疫原性组合物，其包括编码流感病毒H1N1、H3N2、H5N1和H7N9的HA蛋白的四种RNA分子。将该免疫原性组合物包裹在可离子化脂质纳米颗粒中得到mRNA疫苗。本发明的mRNA疫苗具有良好的免疫原性，能够高效表达，可在体内实现稳定安全的表达和有效激活免疫反应，免疫的小鼠可以在体内引起良好的体液免疫，并且有很好的保护作用。本发明的mRNA疫苗作为一种通用型流感疫苗，可提供针对流感病毒的更广泛的保护，具有良好的实际应用价值。

含冰片结构的可电离脂质化合物及其制备方法和应用

Resumen de: CN122647415A

本发明涉及含冰片结构的可电离脂质化合物及其制备方法和应用，属于生物医药技术领域。本发明通过对冰片分子C2位羟基进行修饰，引入多胺结构及疏水性尾链，制得一类新型含冰片结构的可电离脂质化合物。该化合物具有以下优势：（i）冰片结构可有效突破皮肤角质层屏障，显著提升经皮吸收效率；（ii）多胺结构在酸性条件下可电离，通过静电吸附作用高效携载核酸药物，有助于增强核酸稳定性并促进溶酶体逃逸；（iii）尾链修饰增强了化合物的脂溶性，赋予其脂质特性，可作为固体脂质纳米粒的制备原料。本发明还提供了所述化合物的制备方法，该类含冰片结构的可电离脂质化合物在核酸药物的经皮递送领域展现出良好的应用前景。

一种脂质纳米颗粒及其在胞内或体内蛋白质递送中的应用

Resumen de: CN122643257A

本发明公开了一种脂质纳米颗粒及其在胞内或体内蛋白质递送中的应用。本发明所述脂质纳米颗粒包括阳离子脂质、可电离脂质、辅脂脂质、胆固醇和聚乙二醇化脂质五种脂质组分；所述脂质纳米颗粒可以实现高效的活细胞内和体内蛋白质递送，且不影响被递送蛋白质的生物学活性；所述脂质纳米颗粒成分安全，具有很好的生物相容性。本发明具有广泛应用前景。

一种纳米晶氟苯尼考颗粒及其制备方法

Resumen de: CN122643262A

本发明公开了一种纳米晶氟苯尼考颗粒及其制备方法，属于兽药制剂及纳米药物技术领域。所述方法包括：将氟苯尼考溶解于食用级乙醇中制得有机相；将注射用水冷却后加入聚乙二醇‑1000维生素E琥珀酸酯和植酸，制得水相；将两相料液泵入高压微射流对撞反应器中进行连续化混合结晶；产物经减压脱醇、浓缩及干燥，即得类球形纳米晶氟苯尼考颗粒。本发明摒弃了传统有毒溶剂及超声破碎工艺，利用高压微射流的微湍流与植酸的氢键晶面调控作用，一步制备粒径为80～150nm的纳米晶。所得颗粒流动性好、无有毒溶剂残留，25℃下水相溶解度大幅提升，且悬浮稳定性超过120小时。

一种用于治疗肺部肿瘤的药物组合物及其应用

Resumen de: CN122643432A

本发明公开了一种用于治疗肺部肿瘤的药物组合物及其应用。本发明提供的用于治疗肺部肿瘤的药物组合物包括能够肺部递送CXCL10 mRNA的纳米颗粒和靶向基因修饰免疫效应细胞；所述靶向基因修饰免疫效应细胞为CAR‑T细胞、CAR‑NK细胞、CAR‑M细胞或TCR‑T细胞。本发明证实肺部递送CXCL10 mRNA的纳米颗粒能够增强靶向基因修饰免疫效应细胞（如CAR‑T细胞）的肺部肿瘤浸润及抗肿瘤疗效。本发明不仅为肺部肿瘤免疫治疗提供了具有明确机制支撑的可转化方案，也为拓展mRNA药物在肝外器官的递送与多疾病应用场景提供了重要的技术参考与产业化价值。

脂肪间充质干细胞外泌体复合载药凝胶及其制备方法和在制备早产治疗药物中的应用

Resumen de: CN122643235A

本发明涉及药物领域，具体是脂肪间充质干细胞外泌体复合载药递送系统及其制备方法和在制备早产治疗药物中的应用。本发明提供的复合载药递送系统是一种以PLGA包载硝苯地平为内核、AMSC‑Exo为外层的核壳结构微粒，分散于壳聚糖季铵盐‑阿拉伯胶静电复合凝胶基质中，形成载药阴道凝胶。针对早产病理中ROS诱发子宫平滑肌“钙敏感化”而导致宫缩抑制剂药效受限的问题，能够利用AMSC‑Exo激活Nrf2通路清除局部ROS，从上游逆转平滑肌的钙敏感状态，协同增强硝苯地平的抑制宫缩效果。阴道给药后，凝胶滞留于局部，利用阴道‑子宫首过效应使药物优先分布于子宫，减少全身副作用。

一种基于肿瘤抗原表位肽的多靶点DC疫苗及其应用

Resumen de: CN122643427A

一种基于肿瘤抗原表位肽的多靶点DC疫苗及其应用，属于肿瘤免疫治疗技术领域，该疫苗包含hr‑8偶联肽、免疫佐剂和载体，以及免疫记忆增强因子，其中hr‑8偶联肽为hr‑8靶向肽通过化学偶联方式与至少两种不同肿瘤抗原CTL表位肽连接形成的偶联产物，免疫佐剂为TLR9激动剂CpG ODN与TLR3激动剂poly(I:C)的联合佐剂体系，载体为PLGA纳米颗粒，免疫记忆增强因子为IL‑7和/或IL‑15。本发明利用hr‑8肽特异性结合树突状细胞表面DEC‑205受体，实现多靶点抗原的高效协同递送和交叉呈递，联合佐剂与记忆因子显著增强CTL激活并促进长效免疫记忆形成，使得多靶点DC疫苗具有靶向性强、抗原覆盖广、延长无复发生存期的优点。

含有生育酚结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途

Resumen de: CN122647431A

本发明涉及含有生育酚结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途。具体地，提供一种式(1)所示的含有生育酚及其衍生物结构的可电离脂质分子、包含其的脂质纳米颗粒、其制备方法和用途。与本领域常规使用的可电离脂质分子相比，本发明的式(1)所示的可电离脂质分子所制备得到的脂质纳米颗粒可显著提高核酸的递送效率及表达。

一种线粒体靶向自噬抑制聚合物及其制备方法、纳米递送粒子及其制备方法和应用

Resumen de: CN122647718A

本发明涉及靶向纳米颗粒技术领域，特别涉及一种线粒体靶向自噬抑制聚合物及其制备方法、纳米递送粒子及其制备方法和应用。含有三苯基膦基团（triphenylphosphonium，TPP）的高分子TPP‑PEG‑SH（TPS）通过二硫键偶联线粒体自噬抑制剂Mdivi‑1，构建具有线粒体靶向能力及GSH响应性的聚合物TPSM，并进一步与光敏剂IT‑4Cl共组装形成纳米递送系统TPSM@IT‑4Cl。该纳米递送系统具有线粒体靶向能力，促使肿瘤部位氧化应激持续积累，并可在高浓度GSH肿瘤微环境中实现响应性药物释放。

지질 나노입자에 적합한 이온화성 지질

Resumen de: WO2025133951A1

The present disclosure provides nitrogen-containing silicon ether ionizable lipid compounds and lipid nanoparticles including the ionizable lipid. The disclosure further relates to lipid nanoparticles including a provided ionizable lipid compound together with a phospholipid, e.g., a phospholipid that includes at least one unsaturated tail and a head group having a positively charged nitrogen. The provided materials are particularly beneficial in applications involving delivery of a nucleic acid. The disclosure also provides pharmaceutical compositions and methods including the provided ionizable lipids and/or lipid nanoparticles.

仿生普罗布考自组装纳米制剂及其制备方法和应用

Resumen de: CN122643265A

本申请公开一种仿生普罗布考自组装纳米制剂及其制备方法和应用。所述纳米制剂包括由未共价修饰的普罗布考自组装形成的纳米核心、分布于其表面的DSPE‑PEG‑OH修饰组分以及包被于外表面的巨噬细胞来源微囊泡膜层。其制备方法包括制备经DSPE‑PEG‑OH修饰的普罗布考自组装纳米颗粒，对RAW264.7巨噬细胞进行脱水处理和复水处理并离心纯化，以获得巨噬细胞微囊泡，以及将所述纳米颗粒与所述巨噬细胞微囊泡混合并经涡旋和超声处理，以形成微囊泡膜层包被的核壳结构纳米制剂。所述纳米制剂在所测试的水性介质中具有分散稳定性，并在所测试的体内外条件下表现出细胞相容性和生物安全性，可用于制备治疗动脉粥样硬化的药物。

一种以乳清分离蛋白为载体的鞣花酸纳米颗粒及其制备方法和应用

Resumen de: CN122643264A

本发明公开了一种以乳清分离蛋白为载体的鞣花酸纳米颗粒及其制备方法和应用，属于食品加工技术领域。所述制备方法包括如下步骤：将鞣花酸添加至碱性的乳清分离蛋白溶液中，混合均匀后，调节pH至中性；经超声辅助处理后，得到所述鞣花酸纳米颗粒。本发明结合pH驱动方法和超声辅助处理方法，并结合乳清分离蛋白WPI的自身特性，制备了EA包封率高、稳定性强的WPI/EA纳米颗粒，实现了提升EA溶解性、稳定性及生物利用度的效果，为EA的制剂开发与功能活性应用提供了新的制备途径与理论支撑。

一种基于仿生自组装多肽LM2水凝胶介导的GCK递送系统

Resumen de: CN122643231A

针对人参皂苷CK（GCK）水溶性差、生物利用度低及体内滞留时间短等递送难题，本申请构建了一种基于仿生自组装多肽LM2水凝胶介导的GCK递送系统，在抗类风湿关节炎方面表现出较好的治疗效果。

一种通过白蛋白二硫键重组策略构建的卡巴他赛白蛋白纳米粒及其制备方法和应用

Resumen de: CN122643259A

本发明涉及一种通过白蛋白二硫键重组策略构建的卡巴他赛白蛋白纳米粒及其制备方法和应用，属于药物技术领域。所述卡巴他赛白蛋白纳米粒中包含卡巴他赛和二硫键重组的白蛋白，所述二硫键重组的白蛋白通过将白蛋白与还原剂反应后得到。本发明通过还原剂打开白蛋白二硫键再重组载药这一策略，赋予白蛋白纳米粒高稳定性、长循环、及肿瘤微环境智能激活的能力，进而实现高效低毒的治疗效果。本发明制备方法简单，工艺流程简化，获得了在体外与体内实验中均具有显著药效的卡巴他赛白蛋白纳米制剂。

含磺酰胺基团的酯酶响应型PEG化偶联物及其制备方法和应用

Resumen de: CN122643458A

本发明属于生物医药技术领域，具体涉及含磺酰胺基团的酯酶响应型PEG化偶联物及其制备方法和应用。酯酶响应型PEG化偶联物包括：PEG化亲水链段；酯酶可裂解的连接臂，连接臂包含至少一个酯键；含磺酰胺基团的铜死亡增敏功能结构；其中，含磺酰胺基团的铜死亡增敏功能结构通过酯酶可裂解的连接臂与PEG化亲水链段共价连接。本发明提供的含磺酰胺基团的酯酶响应型PEG化偶联物，能够自组装形成纳米颗粒（EsCu@NPs），通过酯酶响应机制在肿瘤部位精准释放L‑BSO和铜离子，高效消耗GSH并诱导铜死亡，进而触发免疫原性细胞死亡（ICD），促进树突状细胞成熟和CD8+T细胞浸润，显著增强抗PD‑1免疫检查点抑制剂的治疗效果。

一种二聚体轮状病毒疫苗及其应用

Resumen de: CN122647621A

本发明提供一种基于VP8‑Fc的融合蛋白，以及以该融合蛋白为核心构建的轮状病毒蛋白亚单位疫苗和mRNA疫苗。动物实验结果显示，无论是蛋白亚单位疫苗还是mRNA疫苗，免疫后均能诱导小鼠产生强烈的体液免疫应答，表现出优异的免疫原性及潜在的交叉保护能力。本发明通过轮状病毒VP8结构域与Fc片段的融合设计，提供了一种能诱导广谱、强效免疫应答的新型轮状病毒疫苗。

一种可电离脂质化合物、包含其的脂质纳米颗粒及其制备方法和应用

Resumen de: CN122647348A

本发明提供了一种可电离脂质化合物、包含其的脂质纳米颗粒及其制备方法和应用。其选自如式（I）所示的可电离脂质或其消旋体、立体异构体、几何异构体、互变异构体、氮氧化物、水合物、同位素标记物、溶剂化物、多晶型物、代谢产物、酯、药学上可接受的盐、前药或其混合物形式；其中，R1和R6各自独立地选自C1‑C20的直链或支链烷基，R2、R5、R7和R8各自独立地为‑(CH2)m‑，m为2至10的整数，R3和R4各自独立地选自H或C1‑C5的烷基，X选自‑O‑、‑S‑或‑Se‑。该化合物化学结构明确、可生物降解，基于其制备的脂质纳米颗粒具有肺部优先富集或肺部靶向递送能力。（I）

一种具有GSH/ROS双重响应机制的聚合物及其制备方法和应用、脂质纳米颗粒

Resumen de: CN122647726A

本发明属于药物递送载体及化疗类药物领域，具体涉及一种具有GSH/ROS双重响应机制的聚合物及其制备方法和应用、脂质纳米颗粒。该聚合物具有GSH/ROS双重响应机制，其化学结构通式如下所示：A‑R‑B；所述A为具有胆固醇或其衍生物的第一化学结构；所述R为具有GSH响应的第二化学结构；所述B为具有如式I所示的第三化学结构。由此，本发明通过化学结构设计赋予其GSH/ROS双重响应机制，并将其进一步应用于药物递送系统及其在肿瘤协同治疗中，实现了基于氧化还原双响应脂质纳米颗粒的多模态协同治疗策略，为恶性肿瘤治疗提供了具有显著协同增强效应的新技术方案。

用于脂质纳米颗粒的可电离脂质

Resumen de: WO2025157978A1

The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.

硼中子俘获治疗用白蛋白纳米平台以及包含该平台的硼中子俘获治疗用组合物

Resumen de: WO2025165163A1

The present invention relates to an albumin nanoplatform for boron neutron capture therapy and a composition for boron neutron capture therapy comprising same. The albumin-based nanoplatform according to the present disclosure can effectively deliver boron to specific tumor tissues by simultaneously conjugating a boron compound containing an excessive amount of boron and a targeting molecule as a carrier for specifically targeting tumor tissues via click chemistry functional groups introduced into the albumin surface. In particular, the nanoplatform enables sufficient delivery of boron molecules to target tumor tissues even at doses less than one-tenth of those required by conventional boron neutron capture therapy (BNCT) drugs, and thus can be applied as a composition for boron neutron capture therapy and as an anticancer therapeutic agent.

基于Gap19多肽的纳米递药系统

Resumen de: CN122643258A

本申请提出基于Gap19多肽的纳米递药系统，该系统由DSPE‑PEG2k‑Gap19与ROS响应材料DSPE‑TK‑PEG5k‑MPC混合制成纳米颗粒，具有双层结构，可增强Gap19的稳定性和血‑脊髓屏障穿透能力。其ROS响应特性可实现损伤微环境触发释药，同时清除活性氧、抑制Cx43半通道活性，协同促进神经修复。实验表明，该系统具有良好的生物相容性、靶向聚集性和功能恢复效果，为脊髓损伤治疗提供了新材料与策略。

含有生育酚结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途

Nº publicación: CN122647430A 28/08/2026

Solicitante:

清华大学

Resumen de: CN122647430A

本发明涉及含有生育酚结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途。具体地，提供一种式(1)所示的含有生育酚及其衍生物结构的可电离脂质分子、包含其的脂质纳米颗粒、其制备方法和用途。与本领域常规使用的可电离脂质分子相比，本发明的式(1)所示的可电离脂质分子所制备得到的脂质纳米颗粒可显著提高核酸的递送效率及表达。